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Abstract
The topic of this thesis is mortality and the prevalence in the UK of ischaemic heart
disease (IHD) and stroke. In particular, we consider changes in each of these between
1981 and 2000 and quantify the extent to which these changes are due to known risk
factors for heart disease: body mass index, diabetes, hypertension, hypercholestero-
laemia.
Chatterjee et al. (2008a) presented a multiple state Markov model for the devel-
opment of heart disease and stroke. We develop two parameterisations for this model,
one consistent with the 1981 prevalences in the UK of all the risk factors, and IHD,
stroke and mortality, and the other consistent with the 2000 prevalences. By taking
the 2000-consistent model and then changing the parameters for a given risk factor
back to those in the 1981-consistent model, we can quantify the effect on IHD, stroke
and mortality if this risk factor had not changed. We also carry out this exercise
changing combinations of risk factors.
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Chapter 1
Introduction
1.1 Introduction
The main aim of this thesis is to investigate the effect of changes in the risk factors
for ischeamic heart disease (IHD) and stroke on the prevalence of IHD and stroke and
on mortality rates. Mortality in the UK changed during the 20th century (Willets
et al., 2004). Tables 1.1 and 1.2 show the number of deaths in England and Wales
(ONS, 2011) in 1981 and 2000 for males and females, respectively. Table 1.3 shows
the standardised number of deaths in 1981 to 2000 populations by sex and age group,
for England and Wales. From the Table 1.3, we can see that if the 2000 populations
experienced the same mortality rates, there will be higher number of deaths in 2000.
These show that there are higher mortality rates in 1981 than 2000, as shown in
Tables 1.1 and 1.2. For age group 55-64, the standardised numbers of deaths in 1981
are 47,685 for males and 26,188 for females so if the 1981 mortality rates continue to
2000, there will be 47,685 more deaths for males and 26,188 more deaths for females
in 2000. We choose years 1981 and 2000 as the time period to be researched and the
reason why we choose 1981 and 2000 will be explained in Section 1.5.
1.2 Trends in mortality rates
Willets et al. (2004) identified five factors leading to mortality improvements: the
cohort effect, the ageing mortality improvement, increased uncertainty at younger
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Age group Male Female
25-34 3181 1821
35-44 5535 3742
45-54 16889 10513
55-64 46858 27211
65-74 92189 62762
75-84 86774 103554
Table 1.1: Number of deaths in 1981 for
males and females.
Age group Male Female
25-34 3849 1702
35-44 6135 3853
45-54 13355 9108
55-64 28003 17722
65-74 60801 42318
75-84 87449 89651
Table 1.2: Number of deaths in 2000 for
males and females.
Age group Male Female
25-34 3407 1998
35-44 6959 4859
45-54 20855 13172
55-64 47685 26188
65-74 93120 56308
75-84 120859 116441
Table 1.3: Standardised number of deaths in 1981 to 2000 populations.
ages as there are many causes of death which are common to young adults, changes
in smoking prevalence and widening social class differentials. For men in their 40s,
the biggest contribution to the improvements came from heart disease, and for women
from improvement in cancer mortality. Men and women in their 50s and 60s have the
highest mortality improvement compared to other age groups. Over the period 1989
to 2001, mortality rates for men in their 50s improved the most among all age groups
by 2.71% and improvement in heart disease mortality contributed two thirds of this
change.
The mortality from cancer, heart disease and stroke has fallen very steadily (Wil-
lets et al., 2004). For men, the greatest reduction came from heart disease mortality
followed by cancer. Factors behind the improvements for heart disease include the
reduction in smoking, improvement in diet, medical advances and drug treatments for
cardiovascular disease. For women at these ages, mortality improvement is dominated
by cancer rather than heart disease. This reflects the improvement in treatment for
cancer, especially breast cancer.
The Office for National Statistics (ONS, 2011) stated that for men and women
aged 65 to 79, the biggest cause of deaths in the UK in 2009 was IHD. For those aged
80 and above, IHD and stroke were the leading causes of death for men and women.
These are the leading causes of deaths for men aged 35 to 64 while for women in this
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age group, the leading cause is breast cancer. Between 1989 and 2001, the largest
improvements in mortality rates happened to age group 60 to 69 for males with an
improvement of 3.35% (Willets et al., 2004). For the same age group, mortality from
heart disease and stroke accounted for 2.08% from the total improvement. Mortality
from heart disease decreased at a higher rate for men and women and there were large
improvements for age group 40 to 64 between 1989 and 2000 (Appendix 1 in Willets
et al., 2004). There was also improvement in stroke mortality in the UK although the
rate of fall is slower than for IHD. The risk factors associated with stroke are similar
to those for IHD.
The trend over time for the mortality rates from IHD has decreased in North
America and many Western Europe countries although for some countries at a slower
rate. Cooper et al. (2000) concluded that IHD mortality is still declining in the US
but at a slower rate than in the 1980s and stroke mortality has had a small decline
since 1990. The age-adjusted IHD mortality rates in the US decreased by more than
3% per year between 1970 and 1990 and 2.7% between 1990 and 1997. In some
developing countries, such as in Russia, the age-standardised death rate from IHD is
575 per 100,000 population in 1982 and increased to 835 per 100,000 population in
2002 (Allender et al., 2007). In Europe, a reduction in age-standardised IHD mortality
has been observed in most countries including Denmark, Netherlands, Norway and
the UK. Romania, Poland and Bulgaria are examples of European countries with
an increasing trend in age-standardised IHD mortality between 1965 and 1998 (Levi
et al., 2002). Among Asian countries that were mentioned by Levi et al. (2002),
which are Hong Kong, Japan and Singapore, only Japan has a decreasing trend in
age-standardised IHD mortality between 1965 and 1998.
1.3 The risk factors and significant events
IHD is the leading cause of death worldwide, followed by stroke (Murray & Lopez,
1997). The major risk factors associated with IHD and stroke, in addition to age,
sex and smoking, are body mass index (BMI), diabetes, hypertension and hyperc-
holesterolaemia. Full descriptions of these risk factors will be given in Section 2.3.
Tables 1.4 and 1.5 show the observed prevalence rates in 1981 and 2000 for males and
females, respectively, taken from Health Survey for England (2006). Prevalence rate
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is defined as the total number of cases of a disease existing in a population divided
by the total population. Shown in the tables are the prevalence of IHD and stroke for
males and females in England and Wales in 1981 and 2000. The observed prevalence
rates for some age groups have shown some improvements and for some age groups
have shown an increase in the IHD observed prevalence rates from 1981 and 2000.
The prevalence of IHD and stroke has not changed much for females where as the
prevalance of IHD and stroke has generally increased for males, particularly for the
75-84 age group.
Despite the improvement in some of the risk factors, the levels of obesity and
diabetes are experiencing an adverse trend. England (2009) reported that in 2007,
almost a quarter of adults were classified as obese. There has been an overall increase
in the prevalence of obesity since 1993. González et al. (2008) reported the rise in
new cases of diabetes: "The rates of diabetes are increasing at a faster rate in the
UK than they are in North America, where prevalence of the condition is one of the
highest in the world".
Tables 1.4 and 1.5 show the prevalence of obesity (BMI > 30) for males and females
from 1981 and 2000. We can see that the observed prevalence rates for obesity have
been increasing over the time period for all age groups for both males and females.
The observed prevalence rates for diabetes have been increasing for most of the
age groups from 1981 to 2000 and the observed prevalence rates are shown in Tables
1.4 and 1.5 for males and females, respectively. From the same tables, we see that
the observed prevalence rates for hypertension (systolic blood pressure > 140 and
diastolic blood pressure > 80) have decreased from 1981 to 2000 for most of the
age groups for males and females. There are positive changes compared to diabetes
and obesity that experienced an adverse trend. The observed prevalence rates for
hypercholesterolaemia (total cholesterol > 200) are shown in Tables 1.4 and 1.5 for
males and females, respectively, in 1981 and 2000. The observed prevalence rates for
hypercholesterolaemia have shown some reduction from 1981 to 2000. These changes
in risk factors will have an impact on the prevalence of IHD, stroke and on mortality
rates. After being attacked with IHD and stroke, the crude risk of death was greatest
in the first year of stroke and particularly in the first 30 days from onset (Hardie et
al., 2005). So it is a significant factor to be looked into. Sudden death is defined as
4
death from any cause within one month following myocardial infarction or stroke.
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Age group IHD Stroke Obesity Diabetes Hypertension Hypercholesterolaemia
1981 2000 1981 2000 1981 2000 1981 2000 1981 2000 1981 2000
25-34 0.41 0.25 0.21 0.05 6.20 20.30 0.00 0.54 23.84 18.07 63.22 53.50
35-44 0.39 0.56 0.00 0.29 9.58 21.30 1.00 2.08 27.68 22.40 89.37 78.60
45-54 2.35 3.28 0.00 0.76 9.53 25.00 2.00 3.18 44.50 34.87 98.84 82.65
55-64 9.98 10.46 2.79 2.95 10.38 25.80 1.14 6.72 58.33 48.00 99.10 83.10
65-74 21.22 20.90 5.85 6.82 8.22 24.47 0.29 8.96 66.42 60.83 99.70 85.35
75-84 16.31 25.55 3.73 10.85 1.43 17.09 2.14 9.22 66.33 67.15 99.90 86.48
Table 1.4: Prevalence rates for males in 1981 and 2000.
Age group IHD Stroke Obesity Diabetes Hypertension Hypercholesterolaemia
1981 2000 1981 2000 1981 2000 1981 2000 1981 2000 1981 2000
25-34 0.10 0.12 0.1000 0.1606 7.74 15.73 0.00 0.78 7.52 6.70 61.14 55.09
35-44 0.30 0.31 0.4000 0.3372 9.04 19.15 1.43 1.14 14.70 10.87 70.10 69.66
45-54 1.30 1.82 0.9000 0.7378 13.43 24.21 1.00 2.00 32.07 24.32 83.91 81.41
55-64 3.50 4.69 2.3000 2.0262 16.09 29.27 0.50 3.74 51.05 42.83 96.93 91.63
65-74 10.00 10.26 4.2000 3.8681 18.66 30.09 1.71 7.32 65.72 58.80 97.26 92.77
75-84 19.30 17.60 10.7000 9.1081 16.31 23.31 0.80 7.52 71.37 69.01 98.80 96.01
Table 1.5: Prevalence rates for females in 1981 and 2000.
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1.4 The IMPACT Model
The IMPACT Model (2007) attempts to explain the decline in IHD deaths between
1981 and 2000 in England and Wales. In particular, IMPACT examines how much of
the decrease in the number of deaths in England and Wales between 1981 and 2000
could be attributed to medical and surgical treatments and how much to changes in
cardiovascular risk factors. The mortality fall from the changes in risk factors is called
the number of deaths prevented or postponed (DPPs). The model is validated by
comparing the estimated and observed mortality decreases for men and women in each
age group.The original IMPACT model is the Scotland IMPACT Model (Capewell et
al., 1999) which explains the decline in IHD deaths in Scotland between 1974 and 1994.
Further development was achieved by adding new risk factors and new treatments in
the English IMPACT Model.
To calculate the mortality fall attributable to a change in a risk factor, the formula
used by the IMPACT Model (2007) to calculate the number of deaths prevented or
postponed, DPPs, is:
DPPs = IHD deaths in 1981× risk factor decline× β coefficient (1.1)
where β coefficient is the value that quantifies the independent relationship between
population change in specific risk factors such as smoking, blood pressure and choles-
terol and the consequent change in population IHD mortality rate. The IMPACT
Model employs the β coefficients that were obtained from large cohort studies and
MONICA analyses (Kuulasmaa et al., 2000). The β coefficients are obtained for spe-
cific IHD risk factors such as smoking, blood pressure and cholesterol. For other risk
factors such as obesity, diabetes and physical activity, there were no suitable β co-
efficients that can describe the relationship so the IMPACT Model uses the relative
risks. These relative risks were taken from the largest and most recent studies.
The β coefficient is used to calculate the mortality reduction as shown in Formula
1.1. For every percentage point fall in the risk factor, the IHD mortality is reduced by
β%. An example of the use of the β coefficient is smoking. Various studies show the
impact of changes in risk factors on changes in IHD mortality. The best estimate for
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the β coefficient for smoking is taken from Sigfusson et al. (1991). This is a study of
IHD in Iceland and shows that every 1% fall in smoking prevalence will decrease the
IHD mortality by 0.51%. Sigfusson et al. (1991) state that the change in risk factor
for smoking for over 20 years is −29.3% for smokers who smoke 1 to 24 cigarettes
daily (or cigars or pipe) and an increase of 3.6% for smokers who smoke more than 25
cigarettes daily. This makes the total fall in smoking risk factor equal to 25.7% (3.6
− 29.3). It is also stated that this reduction decreased the risk of death from IHD by
8% in women and 13% in men. For men, a fall of 25.7% in smoking prevalence will
decrease IHD mortality by 13%. The IMPACT Model uses this study as a reference
to quantify the relationship for smoking.
As IHD mortality has been declining, this model explains how much of the de-
crease in the number of deaths in England and Wales between 1981 and 2000 can be
attributed to medical and surgical treatments and how much to changes in cardiovas-
cular risk factors. The IMPACT Model focuses on the reduction of risk factors and
increases in medical and surgical treatment uptake to calculate the number of deaths
prevented or postponed (DPPs).
The IMPACT Model has some limitations. There is a lack of transparency over
the calculation of the mortality falls over 1981 and 2000 and the β coefficients are
estimated from large studies from out of the UK. The model also lacks flexibility in
terms of time period as we cannot just choose any time period that we want. The
IMPACT Model also considers only IHD–related mortality and does not estimate
the prevalence of IHD and stroke. The results in Unal et al. (2005) are not shown
separately for males and females.
1.5 Aim of the thesis
The problems to be investigated in this thesis are how much of the changes in the
prevalence of IHD/stroke is due to changes in each of the risk factors between 1981
and 2000 and how much of the reduction in mortality is due to changes in each of
the risk factors between 1981 and 2000. We have chosen 1981-2000 as the period over
which we will investigate changes as this is the period covered by the IMPACT model
as explained in Section 1.4. We will focus on ages 45 to 84 last birthday. There are
relatively few deaths and cases of IHD and stroke below age 45 and the upper age
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limit, 84, is the same as the upper limit used for the IMPACT model (Unal et al.,
2005). To carry out this study, we need a model. This model is described in Chapter
2.
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Chapter 2
The Model
2.1 Introduction
In this chapter, we describe the model we use to address the problem outlined in Sec-
tion 1.5. The model is a multiple state model of an individual’s lifetime, incorporating
IHD and stroke and different levels of the risk factors for these events.
One approach to the study of multiple state models is using the transition inten-
sities (TI) (Waters, 1984). By using the transition intensities, the natural setting for
the multiple state models can be kept. As we are using stochastic modelling, any
estimates of TIs derived from data will be subjected to random sampling variation.
There will be a mean and variance matrix. Using the mean and variance matrix, mul-
tiple sets of parameters can be generated and we can use these to assess the impact
of uncertainty by sampling the parameter space a number of times. These estimates
will have a multivariate normal distribution. The TI approach can help to ascertain
the variance of the estimator which can be used in situations if we want to smooth the
parameter estimates while other approaches may not cope with this problem easily.
Waters (1984) explained the TI approach using the example in Figure 2.1. Transfer
is possible between states 1 and 2. State 3 is an absorbing state where transfer from
this state is not possible at all. This is a time continuous Markov chain with a finite
state space. The conditional probabilities are defined as follows: tpghx is the probability
that the individual is in state h at age x+t given that the individual was in state g at
age x. The individual’s state in the future depends only on the state at the present
time and not on the previous history of the individual. The transition intensities are
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Figure 2.1: The basic structure for a 3 states model
then defined and from this, we can derive the probabilities for this model. Differential
equations are derived and solved to calculate the transition probabilities.
Macdonald et al. (2005a) constructed a model for the development of IHD or
stroke that either incorporates or includes pathways through the major risk factors
of interest when underwriting for critical illness insurance. The model is useful in
assessing the impact on insurance underwriting of genetic information relevant to
IHD and/or stroke. It is a multiple state model with three absorbing states, which
are IHD, stroke and dead. The remaining states are all transient. It has different
combinations of the three risk factors, which are hypertension, hypercholesterolemia
and diabetes. Sex, BMI and smoking are also taken as risk factors but are treated
as static risk factors. The Macdonald et al. (2005a) model was parameterized using
data from the Framingham Heart Study, Original Cohort data set, and the model
does not allow for any backward transitions between categories of the risk factors.
The method for estimating the transition intensities uses occurrence/exposure rates
with an assumed Poisson distribution for the number of occurrences and a generalized
linear model (GLM) with a log link to smooth the estimates. The intensities of moving
between categories are calculated for diabetes, hypertension and hypercholesterolemia
and are applied to those still alive who have not yet had an IHD event or a stroke.
Chatterjee et al. (2008a) further developed this model but did not focus on a
specific insurance product. This model uses the same data as Macdonald et al. (2005a)
but also includes the Framingham Offspring and Spouses data set to determine the
structure of the model. Parameters for the transition intensities determined from the
Framingham data were then adjusted by hand so that the model produces prevalence
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rates consistent with the UK observed rates in 2003. Risk factors relevant to heart
disease and stroke are incorporated in the model. It is different from the model
developed by Macdonald et al. (2005a) since it includes BMI and allows backward
transitions. Using this model, which we refer to as the Heriot-Watt Model (HW
model), we can describe an individual’s life history by having certain categories of
risk factors and the effects of the risk factors moving from one level to another in the
long term and we can compute the risk of having IHD and/or a stroke or death.
To produce results, the HW model requires an initial risk profile at the starting age
to specify the distribution over the states in the model as mentioned in Chatterjee
et al. (2008a). The initial profile is a disribution over the states of the model at
the initial age. This model uses the observed prevalence rates from Sproston and
Primatesta (2004) which are the HSE2003 observed prevalence rates for all risk factors
except hypercholesterolaemia as the initial risk profile. For hypercholesterolaemia, the
observed prevalence rates are taken from HSE1994 (Sproston and Primatesta, 2004).
The basic structure of the Chatterjee et al. (2008a) model is similar to Figure 2.1
where the healthy box is equivalent to "Event Free" and sick box is equivalent to "IHD
and/or stroke". One difference is that it is not possible to transfer from "IHD and/or
stroke" to "Event Free". There are 160 different states in the "Event Free" box and
1600 different states in the "IHD and/or stroke" box, one for each combination of the
risk factors and the different IHD and/or stroke events.
2.2 Methodology
In detail, our aims in this thesis are:
(a) to consider the differences between the numbers of deaths in England and Wales
in 1981, standardised to the population in 2000 (Table 1.3), and the actual numbers
of deaths in 2000 (Table 1.2), and to determine the extent to which changes in the
prevalence of IHD and stroke, their risk factors and changes in smoking patterns
account for these differences, and,
(b) to determine the extent to which changes in the observed prevalence rates for
the risk factors for IHD and stroke and changes in smoking patterns account for the
difference between the observed prevalence rates for IHD and stroke from 1981 to
2000.
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We choose 1981 to 2000 as our time interval because this is the time interval used
by the IMPACT model to investigate point (a) above.
Our main tool for this investigation is the HW model (Chatterjee et al. (2008a)).
This is a finite state space Markov model of a human lifetime where the states are all
possible combinations of a set of (discretised) risk facors for IHD and stroke, together
with combinations of conditions which constitute IHD or stroke and, finally, death.
The risk factors for IHD and stroke we consider are:
(i) Obesity
(ii) Diabetes
(iii) Hypertension
(iv) Hypercholesterolaemia
The significant events which constitute IHD or stroke are:
(1) Myocardial infarction
(2) Angina pectoris
(3) Coronary insufficiency
(4) Hard stroke
(5) Transient ischaemic attack
The model is parameterised separately for males and females and the parameteri-
sations depend on the (deterministic) smoking pattern throughout the individual’s
lifetime.
The model is a continuous time model, with time represented by the individual’s
age. Transitions between the states are governed by transition intensities, with the
exception of sudden deaths from IHD or stroke, which are assumed to act immediately
upon the occurrence of IHD or stroke and so are governed by probabilities. The
transition intensities and probabilities of sudden death are functions of the individual’s
age, sex, smoking pattern and of their current state, in terms of risk facors and
significant events; they are not functions of calendar time.
By placing the individual in a given starting state, i.e. combination of levels for the
risk factors and significant events, at a given initial age, the model can be run forward
to any later age, giving probabilities of being in any of the states. However, we will
use the model to determine probabilities/prevalence rates for populations rather than
individuals. We will do this by choosing a given starting age, sex, smoking pattern
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and initial profile. The initial profile is a probability distribution over the states of the
model and represents, for a given point in time, the proportion of the population in
each of these states. Running the model forward we obtain for any later age/calendar
time the prevalence of, for example, diabetes or IHD, and also the proportion of the
population still alive.
We will use two different parameterisations of the HW model:
• a parameterisation which is consistent with observed prevalence rates in 1981 for
the risk factors and significant events, and,
• a parameterisation which is consistent with observed prevalence rates in 2000 for
the risk factors and significant events.
By changing the transition intensities for a given risk factor, or combination of risk
factors, in the "2000 consistent" parameterisation to those from the "1981 consistent"
parameterisation, we can quantify the effect on, say, the prevalence of IHD or the
probability of death from 1981 to 2000 of the change in the risk factor(s).
Chatterjee et al. (2008a) produced a parameterisation of the HW model which is
consistent with observed prevalence rates for the significant events and for different
levels of each risk factor in England and Wales in 2003. They did this, to a large
extent, by using data from the Framingham Heart Study (1948 - 1996) to produce an
initial parameterisation and then manually adjusted this parameterisation so that the
model produced prevalence rates consistent with England and Wales in 2003. Our
approach will be to start with Chatterjee et al. ’s (2008a) parameterisation and to
adjust it manually to fit observed prevalence rates in England and Wales in 1981, and
then separately in 2000. We will make use of some other data sources, particularly
for estimating the probability of sudden death following the onset of IHD or stroke.
To produce either of these two separate parameterisations we need to calculate
the prevalence rates produced by the HW model, and to do this we need to run it
with an intial profile. Suppose, for example, we want an initial profile in 2000 for
males aged 45 with a given smoking profile. The initial profile is the proportion of
this part of the population in each of the states of our model. We can easily find
data sources giving, for example, the proportion of the population in each of the
categories of hypertension and, separately, the proportion in each of the categories
of obesity. However, these are marginal distributions; what we need is the complete
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multivariate distribution. i.e. the proportion of the population in each combination of
the categories of hypertension and obesity, and the other risk factors. To achieve this
we consider the marginal distributions for each risk factor and significant event for
males aged 26 in 1981, with the given smoking profile. We then assume for simplicity
that the distribution over each risk factor and significant event is independent of
the other risk factors and significant events and run the model forward for 19 years.
Running the model forward for 19 years gives prevalence rates in 2000 at age 45 which
are not unduly influenced by the simplifying assumption at age 26. The parameters
of the model can then be adjusted to achieve the required prevalence rates. The same
procedure was used to produce the "1981 consistent" parameterisation using marginal
distributions from 1961 and running the model forward for 20 years.
2.3 Description of the risk factors
The major risk factors, in addition to age, sex and smoking which are deterministic fac-
tors, are body mass index (BMI), diabetes, hypertension and hypercholesterolaemia.
The risk factors are categorized into a small number of discrete levels as shown below:
• Diabetes: 2 levels shown in Table 2.1 where values are shown in two units,
mg/dL and mmol/L,
• BMI: this is defined as Weight (kgs)/Height (mtrs2). There are 5 levels as shown
in Table 2.2,
• Hypertension: 4 levels determined by measurements of systolic (SBP) and di-
astolic blood pressure (DBP) as shown in Table 2.3. If the measurements of
SBP and DBP indicate two different categories, the individual is assigned to
the higher category of hypertension,
• Hypercholesterolaemia: 4 levels as shown in Table 2.4 where values are shown in
terms of low density cholesterol (LDL) and total cholesterol (TC) in two units,
mg/dL and mmom/L,
• Significant Events: the HW model has 11 conditions which are new myocardial
infarction, angina pectoris, coronary insufficiency, transient ischaemic attack,
new hard stroke, old myocardial infarction, old hard stroke, new hard stroke
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from old myocardial infarction, new myocardial infarction from old hard stroke,
old myocardial infarction and hard stroke, and dead.
Category Term Blood glucose (mg/dL) Blood glucose (mmol/L)
0 Non-diabetic < 126 < 7
1 Diabetic ≥ 126 ≥ 7
Table 2.1: Categories of diabetes.
Category Term BMI
0 Underweight ≤ 18.5
1 Lightweight 18.5–25
2 Overweight 25–30
3 Obese 30–40
4 Morbidly Obese > 40
Table 2.2: Categories of body mass index.
Category SBP (mmHg) DBP (mmHg)
0 < 120 < 80
1 120–139 80–89
2 140–159 90–99
3 ≥ 160 ≥ 100
Table 2.3: Categories of hypertension.
16
Category LDL (mg/dL) LDL (mmol/L) TC (mg/dL) TC (mmol/L)
0 < 130 < 3.362 < 200 < 5.17
1 130–160 3.362–4.138 200–230 5.17–5.95
2 160–190 4.138–4.913 230–260 5.95–6.72
3 ≥ 190 ≥ 4.913 ≥ 260 ≥ 6.72
Table 2.4: Categories of hypercholesterolaemia.
2.4 Calculation procedures
The HW model involves the Kolmogorov forward differential equations in order to
calculate the occupancy probabilities between states after the parameters are known
and the initial risk profile is included in the model. The numerical solution to these
Kolmogorov forward differential approximations is found by using the Runge-Kutta
method of order 4 and we will do the calculations in C++. The Kolmogorov forward
differential equations for this process starting in state a are
∂
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kj
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We can re-write these equations as:
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Let h be a given step size. For j = 0, 1, . . . n we calculate successively:
k1,j = hfj(t; tpa0x , tp
a1
x , . . . , tp
an
x ) (2.6)
k2,j = hfj(t+ h/2; tpa0x + k1,0/2, tp
a1
x + k1,1/2, . . . , tp
an
x + k1,n/2) (2.7)
k3,j = hfj(t+ h/2; tpa0x + k2,0/2, tp
a1
x + k2,1/2, . . . , tp
an
x + k2,n/2) (2.8)
k4,j = hfj(t+ h; tpa0x + k3,0, tp
a1
x + k3,1, . . . , tp
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x + k3,n) (2.9)
Then:
t+hp
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≈ tp
aj
x0
+ (k1,j + 2k2,j + 2k3,j + k4,j)/6 (2.10)
We will model the probability of sudden death following myocardial infarction or
stroke using the R statistical package.
2.5 Data Requirements
We will need data to build the initial risk profiles in 1961 and 1981. If these rates are
not available, we will interpolate or extrapolate using available data. We also need
information on the population of England and Wales and smoking rates for males and
females for all age group. We discuss the data that will be used and the prevalence
rates in 1981 and 2000 will be shown together with prevalence rates from other sources
in Chapter 3.
For the initial risk profiles and observed prevalence rates, data will be taken from:
(i) The National Heights and Weights Survey 1980 (HWS80) for the prevalence of
BMI.
(ii) The Health and Lifestyle Survey 1984-1985 (HALS84) for the prevalences of
BMI, diabetes and hypertension.
(iii) Data from the Health Survey for England (HSE, 2006) show for each sex and
in, mostly, 10–year age groups, the proportion of the population of England and
Wales in 1994, 1998, 2003 and 2006 with diabetes, in each of 5 categories of
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BMI, in each of 4 categories of hypertension, in each of 2 categories of hyper-
cholesterolaemia and in each of 4 categories of ‘significant event’ (‘Event free’,
MI, HS or MI+HS).
For the population of England and Wales, data will be taken from the Office for
National Statistics (ONS). Whereas data for the smoking rates will be taken from
the ONS (Robinson & Lader, 2007) which give the percentages of the population of
England and Wales in 1981 who were current smokers, CS, ex–smokers, XS, or had
never smoked, NS.
To model the probability of sudden deaths following myocardial infarction or
stroke, we will use these data:
(i) Data from the Framingham Heart Study for the original cohort (OC) which
started in 1948 for Exam 1 to Exam 20 in 1986.
(ii) Data from the Framingham Heart Study for the offspring and spouses cohort
(OS) which started in 1971 for Exam 1 with further examinations average 6
years apart. We have the data up to Exam 6 which was done around 1997.
Finally, we will need data from the ONS that show the mortality rates in 1981
and 2000 from ELT14 (ONS, 2007) and ELT16 (ONS, 2009) for each sex and age.
2.6 Thesis Outline
In Chapter 3 we discuss the various data sources that we will use in this thesis as
mentioned in Section 2.5 and combine the observed prevalence rates for all available
years to compare.
In Chapter 4 we discuss the adjustments to sudden deaths that will be applied
to the HW model. This is then followed by adjustments to the other risk factors to
match the HW model with 1981 and 2000 observed prevalence rates in Chapter 5.
In Chapter 6, we analyse the effect of changes in the risk factors between 1981
and 2000 and calculate the number of IHD events, stroke events and deaths due to
changes in the associated risk factors. We investigate the effect of changes in a single
factor and then the effect of changes in combinations of risk factors. In Chapter 7
we state our conclusions and discuss further work to be researched. Throughout this
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thesis the term ‘rate’ refers to prevalence rate for a risk factor (or mortality rate if
appropriate), unless otherwise stated.
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Chapter 3
Data
3.1 Introduction
As mentioned in Section 2.5, we need data to calculate the observed prevalence rates
for independent initial risk profiles in 1961 (denoted as P ind1961x (i)) and 1981 (denoted
as P ind1981x (i)) to run the HW model. We also need observed prevalence rates in 1981
and 2000. If these rates are not available, we will interpolate or extrapolate using
available data. We discuss the data that will be used and the observed prevalence
rates in 1981 and 2000 will be shown together with observed prevalence rates from
other sources.
3.2 Different Sources of Data
For our study, we need data such as the population of England and Wales, smoking
rates and observed prevalence rates for the risk factors. All data used in this study
are explained below. We use these data to calculate the observed prevalence rates in
1981 and 2000.
(i) Data from the Office for National Statistics (ONS) show the mid–year popula-
tion of England and Wales in 1981 for integer ages last birthday for each sex
(ONS, 1981). Table 3.1 shows the population at selected ages for males and
females.
(ii) Data from the ONS (Robinson & Lader, 2007) give the percentages of the popu-
lation of England and Wales in 1981 who were current smokers, CS, ex–smokers,
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XS, or had never smoked, NS. Corresponding figures are given for the year
2000. These percentages are given separately for each sex and in, mostly, 10–
year age groups. They are presented here as Tables 3.2, 3.3 and 3.4. Using linear
interpolation between the mid–points for each age group, we can estimate the
proportion of the population of England and Wales for each smoking status,
SS, categorised by single years of age x and sex G.
(iii) Data from the Health Survey for England (Sproston & Primatesta, 2004) show
for each sex and in, mostly, 10–year age groups, the proportion of the popu-
lation of England and Wales in 1994, 1998, 2003 and 2006 with diabetes, in
each of 5 categories of BMI, in each of 4 categories of hypertension, in each of
2 categories of hypercholesterolaemia and in each of 4 categories of ‘significant
event’ (‘Event free’, MI, HS or MI+HS). The categories for hypertension and
hypercholesterolaemia are shown in Tables 3.5 and 3.6 for hypertension and
hypercholesterolaemia. For diabetes and BMI, the categories follow the same
definition as in the HW model, shown in Tables 2.1 and 2.2. The prevalence
of hypertension are given in Table 7.16 from Sproston & Primatesta (2004) as
the normotensive treated, normotensive untreated, hypertensive treated and hy-
pertensive untreated rates. To find the observed prevalence rates based on the
categories of hypertension defined in the HW model, we use the normotensive
treated and normotensive untreated rates as equivalent to hypertension levels
0 and 1 and we use the hypertensive untreated and treated rates as equivalent
to levels 2 and 3. The hypertensive rates given in Table 7.16 are defined as
those with SBP ≥ 140 mmHg and DBP ≥ 90 mmHg. To separate the observed
prevalence rates for levels 2 and 3, we use the extra information in Table 7.17
(Sproston & Primatesta, 2004) where it includes the observed prevalence rates
for hypertensive with SBP ≥ 160 mmHg and DBP ≥ 95 mmHg which is equal
to the rates for hypertension level 3, based on the HW model categories. So in
order to get the observed prevalence rates for level 2, we substract the informa-
tion for hypertensive untreated and treated rates in Table 7.16 with the rates
in Table 7.17. For hypercholesterolaemia, we subtract from the observed preva-
lence rates where HSE defines hypercholesterolaemia as greater than 5.0mmol/l
to get hypercholesterolaemia level 0 based on the HW model definition. Extra
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information on the observed prevalence rates based on definition of hypercholes-
terolaemia in HSE98 (greater than 6.5mmol/l) will be hypercholesterolaemia
level 3 in the HW model. Using linear interpolation between the mid–points
for each age group, we can estimate the proportion of the population of Eng-
land and Wales in each category for each risk factor separately, categorised
by single years of age x and sex G. We denote these proportions for year n
ΠDiab,n(iD | x,G), ΠBMI,n(iB | x,G), ΠHtens,n(iHT | x,G), ΠHchol,n(iHC | x,G)
and ΠSigEv,n(iSE | x,G), respectively. More precisely, iD, iB, iHT , iHC and iSE
are levels for diabetes, BMI, hypertension, hypercholesterolaemia and signifi-
cant events, respectively. Tables 3.7 and 3.8 show the extrapolated risk profiles
in 1981 and 1961 using available data from Health Survey of England (Sproston
& Primatesta, 2004).
(iv) Data from the UK Data Archive (UKDA) such as the National Heights and
Weights Survey 1980, the Health and Lifestyle Survey 1984-1985 and the Di-
etary and Nutritional Survey of British Adults 1986-1987 data sets should pro-
vide information on individuals in 1980 and 1986 categorised by age, sex, smok-
ing status, diabetes, BMI, hypertension, hypercholesterolaemia and significant
event. Using these data, we can categorise the observed prevalence rates using
the same definition of the category levels as the HW Model as mentioned in
Tables 2.1, 2.2, 2.3 and 2.4.
(a) The National Heights and Weights Survey 1980 (HWS80) represents the
heights and weights among the adult population of Great Britain aged 16
and over. It is a one-time study with 10,018 respondents. Variables such
as age, sex, weight and height are available in the dataset and this will
allow us to calculate the prevalence of BMI by age and sex in 1980.
(b) The Health and Lifestyle Survey 1984-1985 (HALS84) was designed to
describe self-reported health, attitudes to health and beliefs about causes of
disease in relation to measurement of health and lifestyle in adults of Great
Britain. This study is a longitudinal study for adults aged 18 and over in
Great Britain in 1984−1985 with 9,000 respondents. The second follow–up
survey was conducted in 1991−1992 (HALS91). HALS84 contains variables
that are needed to find the prevalence of BMI, hypertension and diabetes
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in 1984−1985. Measurements such as weight, height and blood pressure
were taken during the visit by a nurse and questions on diabetes were also
asked. For diabetes, the observed prevalence rates are calculated based
on self-reported health. The question asked is if the respondent has any
long-standing illness, disability or infirmity. The codes are 1 for ‘yes, this
condition is declared’ and 9 for ‘condition not declared’ for diabetes.
(c) The Dietary and Nutritional Survey of British Adults 1986-1987 (DNS86)
involved 1,775 adults in Great Britain, aged 16 to 64. It was a one-time
study and the purpose was to produce data on food and nutrient intake, nu-
tritional status, anthropometric and blood pressure measurements. Their
body measurements were also taken, so we have data on their weight and
height. Although this study enables us to calculate the prevalence of obe-
sity and hypertension, the data are not given by age and sex. The study
also provides analysis on urine, haematology, serum and plasma. This pro-
vides results on the total cholesterol level for each respondent and allows
us to calculate the prevalence of hypercholesterolaemia by age and sex in
1986-87.
These data will be used to model the probability of sudden deaths following myocardial
infarction and hard stroke which will be explained in Chapter 4:
(i) Data from the Framingham Heart Study for the original cohort (OC) which
started in 1948 for Exam 1 to Exam 20 in 1986.
(ii) Data from the Framingham Heart Study for the offspring and spouses cohort
(OS) which started in 1971 for Exam 1 with further examinations average 6
years apart. We have the data up to Exam 6 which was done around 1997.
The population data outlined in (i) and (ii) allow us to calculate (approximately):
N1981(x | G, SS), the population of England and Wales in 1981 categorised by
age, sex and smoking status.
However, the data in (iii) do not allow us to split N1981(x | G, SS) by the level of each
of the risk factors because the proportions in (iii) are not given separately for each
smoking status.
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Age Male Female
20 402.8 391.2
30 341.1 335.3
40 268.9 265.0
50 281.9 282.5
60 301.1 330.1
70 199.1 258.8
Table 3.1: Population of England and Wales in 1981 for selected ages (in thousands).
Age Male (%) Female (%)
1981 2000 1981 2000
20-24 42 35 40 35
25-34 43.5 39 40.5 32
35-49 42.5 31 40.5 27
50-59 44.5 27 42 28
60+ 34 16 23 15
Table 3.2: Prevalence of current smokers.
Age Male (%) Female (%)
1981 2000 1981 2000
20-24 9 7 9 11
25-34 19.5 12 14.5 13
35-49 30.5 20 14.5 19
50-59 37.5 36 19 24
60+ 46 52 19 29
Table 3.3: Prevalence of ex–smokers.
Age Male (%) Female (%)
1981 2000 1981 2000
20-24 49 58 51 54
25-34 37 49 45 54
35-49 27 49 45 54
50-59 18 37 39 48
60+ 20 32 58 56
Table 3.4: Percentage who have never smoked.
3.3 Risk Factors Prevalence Rates
We use the data mentioned in the previous section and here we discuss how the
observed prevalence rates for each risk factor in 1981 and 2000 are calculated.
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Category Definition
Normontensive untreated SBP < 140 mmHg and DBP < 90 mmHg, not currently
taking drug specifically prescribed to treat their
high blood pressure.
Normontensive treated SBP < 140 mmHg and DBP < 90 mmHg, currently
taking drug specifically prescribed to treat their
high blood pressure.
Hypertensive treated SBP ≥ 140 mmHg and DBP ≥ 90 mmHg, not currently
taking drug specifically prescribed to treat their
high blood pressure.
Hypertensive untreated SBP ≥ 140 mmHg and DBP ≥ 90 mmHg, not currently
taking drug specifically prescribed to treat their
high blood pressure.
Table 3.5: Categories of hypertension.
Category TC (mmol/l)
H’chol HSE03 ≥ 5.0
H’chol HSE98 ≥ 6.5
Table 3.6: Categories of hypercholesterolaemia.
Risk factor Male Female
20-24 25-34 35-44 45-54 55-64 20-24 25-34 35-44 45-54 55-64
Diabetes
0 100 100 100 100 99 100 100 100 99.9 99.8
1 0 0 0 0 1 0 0 0 0.1 0.2
BMI
0 1.1 3.4 0.0 0.0 1.3 2.9 2.6 2.6 2.3 1.3
1 74.6 70.9 64.0 47.0 40.9 76.8 86.1 76.5 62.1 39.3
2 24.3 25.7 36.0 51.5 53 20.3 11.3 20.8 35.3 46.8
3 0.0 0.0 0.0 0.9 0.2 0.0 0.0 0.2 0.3 12.6
4 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0
H’ten
0 20 24 20 9 5 2 3 4 1 3
1 25 25 20 8 6 78 65 58 22 7
2 48 38 40 45 44 15 24 28 45 45
3 7 13 20 38 45 5 8 10 32 45
H’chol
0 15 8.8 1.4 3.6 2 26.3 30 26.1 8.5 2
1 35 10 7.9 5.7 4 32 25 23.9 10.5 10
2 35 39 35 30.5 25 33.6 40 47 25 12
3 15 42.2 55.7 60.2 69 8.1 5 3 56 76
Events
¨ Event free¨ 99.9 99.7 99.4 89.4 85.5 100 99.5 99.3 92.9 92.6
MI 0 0.2 0.5 5 6.3 0 0.2 0.3 6.8 6.9
HS 0.1 0.1 0.1 3.6 4.9 0 0.2 0.2 0.1 0.2
MI + HS 0 0 0 2 3.3 0 0.1 0.2 0.2 0.3
Table 3.7: Risk profiles by categories (percentages) in England and Wales in 1961.
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Risk factor Male Female
20-24 25-34 35-44 45-54 55-64 20-24 25-34 35-44 45-54 55-64
Diabetes
0 100 99.1 99.1 99.1 97.3 100 100 100 100 97.3
1 0 0.9 0.9 0.9 2.7 0 0 0 0 2.7
BMI
0 3.3 2.2 0.2 0.7 0.4 4.5 2.4 1.9 1.5 1.3
1 69.1 60.7 49.5 40.1 40.7 71.1 70.7 63.0 53.0 36.4
2 25.1 35.1 44.2 53.1 55.5 21.0 19.8 25.5 37.5 41.8
3 2.5 2.0 6.1 1 3.4 3.2 6.6 9.2 14.5 19.3
4 0.0 0.0 0.0 0.0 0.0 0.2 0.5 0.4 0.0 1.2
H’ten
0 34.2 32.2 30.2 20.8 12.8 7.6 9 10 2 5.6
1 32.2 31.2 30.3 20.6 6.9 79 78 72 48.6 18.4
2 31.9 29.9 27.9 35.2 39.7 13.4 12 14 33 37.8
3 1.7 6.7 11.6 23.4 40.6 0 1 4 16.4 38.2
H’chol
0 58.9 34.8 10.6 11.3 5 47.8 38.9 29.9 16 3.1
1 18.3 19.8 21.4 19.2 19.5 22.7 21.2 19.8 15.2 11.7
2 19.6 23.7 27.8 23.5 24.5 23.8 31.9 40.1 27.8 14.3
3 3.2 21.7 40.2 46 51 5.7 8 10.2 41 70.9
Events
¨ Event free¨ 100 99.9 99.7 99.4 88.3 100 100 99.9 99.8 92.8
MI 0 0 0.2 0.5 7.8 0 0 0 0.1 6
HS 0 0.1 0.1 0.1 2.6 0 0 0.1 0.1 0.1
MI + HS 0 0 0 0 1.3 0 0 0 0 0.2
Table 3.8: Risk profiles by categories (percentages) in England and Wales in 1981.
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3.3.1 Body Mass Index
For BMI observed prevalence rates, we will interpolate the 1981 observed prevalence
rates using the HWS80 and HALS84 observed prevalence rates. The data are taken
from the measurements for heights and weights during a nurse visit. These should
provide reliable data to calculate the BMI observed prevalence rates in 1980 and 1984,
respectively, for each age and sex. The observed prevalence rates for 2000 are taken
from the Adult Trend Tables 2006 (NHS, 2006).
Figures 3.1, 3.2 and 3.3 show the observed prevalence rates for BMI level 0 for
males taken from Framingham Study exams 1 to 6, UK data sources and UK data
sources and Framingham exam 3 (1981), respectively. Figures 3.16, 3.17 and 3.18
show the same graphs for females. In the Framingham Study, there was no clear
trend in the prevalence of BMI 0 over time for males and females. Figures 3.4 and 3.5
show the observed prevalence rates for BMI level 1 for males taken from Framingham
Study exams 1 to 6 and UK data sources, respectively. Figure 3.6 shows the observed
prevalence rates from UK data sources together with the Framingham exam 3 (1981).
For females, these are shown in Figures 3.19, 3.20 and 3.21. Prevalence of BMI levels
0 and 1 in the UK are higher than in the Framingham Study for the same time period
as we can see in Figure 3.3, where the observed prevalence rates in Exam 3 are lower
than the interpolated 1981 observed prevalence rates. The observed prevalence rates
for BMI level 1 for males and females decreased over time in Framingham and in the
UK. The same trend can also be seen in BMI level 2 in Figures 3.7 and 3.8 for males
and 3.22 and 3.23 for females for Framingham Study observed prevalence rates and
UK data sources observed prevalence rates.
An increasing trend can be seen in BMI level 3 in the Framingham and UK ob-
served prevalence rates in Figures 3.10 and 3.11 for males and Figures 3.25 and 3.26
for females. There is no clear trend for BMI level 4 for males in the Framingham
observed prevalence rates, shown in Figure 3.13, but increasing trends are shown
in Figure 3.14 for males and Figures 3.28 and 3.29 for females. Although the 1981
observed prevalence rates from the interpolation do not have the same level as the
observed prevalence rates from Framingham Exam 3 for males, which are from the
same year, the observed prevalence rates from HWS80 and HALS84 are reliable and
follow the same trend as the HSE observed prevalence rates. Figures 3.21, 3.24, 3.27
28
and 3.30 for females show that the Framingham observed prevalence rates in Exam
3 are quite close to the observed prevalence rates in the 1980s except for level 0 in
Figure 3.18.
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Figure 3.1: Prevalence of BMI level 0 for
males in Framingham.
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Figure 3.2: Prevalence of BMI level 0 for
males in the UK.
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Figure 3.3: Prevalence of BMI level 0 for
males in the UK and Framingham.
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Figure 3.4: Prevalence of BMI level 1 for
males in Framingham.
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Figure 3.5: Prevalence of BMI level 1 for
males in UK.
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Figure 3.6: Prevalence of BMI level 1 for
males in UK and Framingham.
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Figure 3.7: Prevalence of BMI level 2 for
males in Framingham.
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Figure 3.8: Prevalence of BMI level 2 for
males in the UK.
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Figure 3.9: Prevalence of BMI level 2 for
males in the UK and Framingham.
32
10 20 30 40 50 60 70 80
0
.
0
0
.
1
0
.
2
0
.
3
0
.
4
Age
P
r
e
v
a
l
e
n
c
e
Exam 1
Exam 3
Exam 4
Exam 5
Exam 6
Figure 3.10: Prevalence of BMI level 3
for males in Framingham.
10 20 30 40 50 60 70 80
0
.
0
0
.
1
0
.
2
0
.
3
0
.
4
Age
P
r
e
v
a
l
e
n
c
e
1981 rates
HWS80
HALS84
HSE94
2000 rates
HSE03
Figure 3.11: Prevalence of BMI level 3
for males in the UK.
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Figure 3.12: Prevalence of BMI level 3
for males in the UK and Framingham.
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Figure 3.13: Prevalence of BMI level 4
for males in Framingham.
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Figure 3.14: Prevalence of BMI level 4
for males in the UK.
10 20 30 40 50 60 70 80
0
.
0
0
0
.
0
2
0
.
0
4
0
.
0
6
0
.
0
8
0
.
1
0
Age
P
r
e
v
a
l
e
n
c
e
Exam 3
1981 rates
HWS80
HALS84
HSE94
2000 rates
HSE03
Figure 3.15: Prevalence of BMI level 4
for males in the UK and Framingham.
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Figure 3.16: Prevalence of BMI level 0
for females in Framingham.
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Figure 3.17: Prevalence of BMI level 0
for females in the UK.
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Figure 3.18: Prevalence of BMI level 0
for females in the UK and Framingham.
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Figure 3.19: Prevalence of BMI level 1
for females in Framingham.
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Figure 3.20: Prevalence of BMI level 1
for females in the UK.
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Figure 3.21: Prevalence of BMI level 1
for females in the UK and Framingham.
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Figure 3.22: Prevalence of BMI level 2
for females in Framingham.
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Figure 3.23: Prevalence of BMI level 2
for females in the UK.
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Figure 3.24: Prevalence of BMI level 2
for females in the UK and Framingham.
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Figure 3.25: Prevalence of BMI level 3
for females in Framingham.
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Figure 3.26: Prevalence of BMI level 3
for females in the UK.
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Figure 3.27: Prevalence of BMI level 3
for females in the UK and Framingham.
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Figure 3.28: Prevalence of BMI level 4
for females in Framingham.
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Figure 3.29: Prevalence of BMI level 4
for females in the UK.
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Figure 3.30: Prevalence of BMI level 4
for females in the UK and Framingham.
39
3.3.2 Diabetes
For diabetes, we have data from the Health and Lifestyle Survey 1984-1985 (HALS84)
where diabetes is a self-reported condition. This is also the same as in the Health
Survey for England (HSE). We use these observed prevalence rates as HLS84 has the
same condition as HSE and it also follows the same trends as HSE and Framingham.
As we only have one dataset for diabetes that represents the 1980s, we extrapolate
the 1981 observed prevalence rates using HALS84 and HSE1991.
Figures 3.31, 3.32 and 3.33 show the diabetes rates from Framingham Study, UK
data sources and UK data sources and Framingham Study Exam 3, respectively. No
clear time trend can be seen from Figure 3.31 but we can see an increasing trend over
time in the UK data sources observed prevalence rates. Figures 3.34, 3.35 and 3.36 are
the observed prevalence rates for females and follow the same trend as males. Figures
3.31 and 3.36 show that the observed prevalence rates from Framingham Study Exam
3 that took place in 1981 are higher than the 1981 observed prevalence rates that
we have extrapolated from HALS84 and HSE91. However, for diabetes, we use data
from HALS84 and HSE91 as the data are reliable. For the observed prevalence rates
in 2000, we interpolate the HSE observed prevalence rates which are available in 1998
and 2003 in NHS (2006).
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Figure 3.31: Prevalence of diabetes for
males in Framingham.
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Figure 3.32: Prevalence of diabetes for
males in the UK.
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Figure 3.33: Prevalence of diabetes for
males in the UK and Framingham.
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Figure 3.34: Prevalence of diabetes for
females in Framingham.
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Figure 3.35: Prevalence of diabetes for
females in the UK.
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Figure 3.36: Prevalence of diabetes for
females in the UK and Framingham.
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3.3.3 Hypertension
For hypertension, we will use data from HALS84 and HALS91 to extrapolate the 1981
observed prevalence rates. Although the trend over time is not consistent with HSE
as shown in Figures 3.41 and 3.44, these surveys are reliable to represent the trend
and observed prevalence rates in the 1980s. Some rates are also consistent with the
Framingham observed prevalence rates for Exam 3 which was carried out in 1981.
For 2000 observed prevalence rates, we interpolate the observed prevalence rates from
HSE94 and HSE03 taken from Sproston & Primatesta (2004) for males and females.
Figures 3.37, 3.38 and 3.39 show the observed prevalence rates for hypertension
level 0 from Framingham Study Exams 1 to 6, UK data sources and UK data sources
and Framingham Exam 3, respectively. Increasing trend over time can be seen in
Figures 3.37 and 3.38. The Exam 3 observed prevalence rates from the Framingham
Study (1981) is higher than the 1981 observed prevalence rates in the UK, as shown
in Figure 3.39. Hypertension level 1 observed prevalence rates for males are shown in
Figures 3.40, 3.41 and 3.42 from Framingham Study Exams 1 to 6, UK data sources
and UK data sources and Framingham Exam 3, respectively. As mentioned before,
the UKBA observed prevalence rates have different trends than the HSE observed
prevalence rates and the 1981 Exam 3 observed prevalence rates from the Framingham
Study are close to UK observed prevalence rates in 2000 which can be seen in Figures
3.41 and 3.42, respectively.
Figure 3.43 shows the observed prevalence rates for level 2 from the Framingham
Study and we can see there is a decreasing trend over time. The trend is similar
to the trend in HSE observed prevalence rates as shown in Figure 3.44 and we can
see in Figure 3.45 that the Exam 3 observed prevalence rates from the Framingham
Study are close to the observed prevalence rates in 1980s. Figures 3.46, 3.47 and
3.48 show the observed prevalence rates for hypertension level 3 from Framingham
Study Exam 1 to 6, UK data sources and UK data sources and Framingham Exam 3,
respectively. A decreasing trend over time can be seen in Figures 3.46 and 3.47 but
the observed prevalence rates in Exam 3 from the Framingham Study are lower than
the UK observed prevalence rates, as shown in Figure 3.48.
The increasing trend over time for level 0 is also similar for females as shown in
Figure 3.49 and in the HSE observed prevalence rates in Figure 3.50. Exam 3 observed
43
rates from the Framingham Study have similar trends as the UKBA observed rates,
shown in Figure 3.51. Figures 3.52, 3.53 and 3.54 show the observed prevalence rates
for hypertension level 1 for females from Framingham Study Exam 1 to 6, UK data
sources and UK data sources and Framingham Exam 3, respectively. There is a
decreasing trend shown in Figure 3.52 and the trend over age for UKBA observed
prevalence rates is similar to Exam 3 observed prevalence rates from the Framingham
Study, shown in Figure 3.54.
Figures 3.55, 3.56 and 3.57 show the observed prevalence rates for hypertension
level 2 and Figures 3.58, 3.59 and 3.60 show the observed prevalence rates for hy-
pertension level 3 from Framingham Study Exams 1 to 6, UK data sources and UK
data sources and Framingham Exam 3, respectively. The trends between the UKDA
observed prevalence rates are similar to HSE observed prevalence rates and Exam 3
observed prevalence rates from the Framingham Study for levels 2 and 3, but the levels
are different. As we can see from Figures 3.56 and 3.59, the 1980s observed prevalence
rates are in between with observed prevalence rates from HSE94 and HSE2000.
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Figure 3.37: Prevalence of hypertension
level 0 for males in Framingham.
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Figure 3.38: Prevalence of hypertension
level 0 for males in the UK.
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Figure 3.39: Prevalence of hypertension
level 0 for males in the UK and
Framingham.
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Figure 3.40: Prevalence of hypertension
level 1 for males in Framingham.
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Figure 3.41: Prevalence of hypertension
level 1 for males in the UK.
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Figure 3.42: Prevalence of hypertension
level 1 for males in the UK and
Framingham.
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Figure 3.43: Prevalence of hypertension
level 2 for males in Framingham.
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Figure 3.44: Prevalence of hypertension
level 2 for males in the UK.
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Figure 3.45: Prevalence of hypertension
level 2 for males in the UK and
Framingham.
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Figure 3.46: Prevalence of hypertension
level 3 for males in Framingham.
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Figure 3.47: Prevalence of hypertension
level 3 for males in the UK.
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Figure 3.48: Prevalence of hypertension
level 3 for males in the UK and
Framingham.
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Figure 3.49: Prevalence of hypertension
level 0 for females in Framingham.
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Figure 3.50: Prevalence of hypertension
level 0 for females in the UK.
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Figure 3.51: Prevalence of hypertension
level 0 for females in the UK and
Framingham.
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Figure 3.52: Prevalence of hypertension
level 1 for females in Framingham.
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Figure 3.53: Prevalence of hypertension
level 1 for females in the UK.
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Figure 3.54: Prevalence of hypertension
level 1 for females in the UK and
Framingham.
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Figure 3.55: Prevalence of hypertension
2 1 for females in Framingham.
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Figure 3.56: Prevalence of hypertension
level 2 for females in the UK.
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Figure 3.57: Prevalence of hypertension
level 2 for females in the UK and
Framingham.
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Figure 3.58: Prevalence of hypertension
level 3 for females in Framingham.
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Figure 3.59: Prevalence of hypertension
level 3 for females in the UK.
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Figure 3.60: Prevalence of hypertension
level 3 for females in the UK and
Framingham.
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3.3.4 Hypercholesterolaemia
For hypercholesterolaemia, we have one data souce from the Dietary and Nutritional
Survey 1984 (DNS84). We will not use the observed prevalence rates from the dataset
as it represents a small study which consists of 919 males and 856 females and would
not be a reliable source for observed prevalence rates in the 1980s. The time trend is
also different from HSE and the highest age in the dataset is 64. We need observed
prevalence rates for higher ages as we are interested in rates for 45 to 80. So we will
extrapolate the 1981 observed prevalence rates using the HSE1994 and 2003 observed
prevalence rates and interpolate these rates to get the 2000 observed prevalence rates.
Figures 3.61, 3.62 and 3.63 show the observed prevalence rates for hypercholestero-
laemia level 0 for males from Framingham Study Exam 1 to 6, UK data sources and
UK data sources and Framingham Exam 3, respectively. The trends in the observed
prevalence rates from the Framingham Study and UK data sources for level 0 are
increasing as shown in Figures 3.64 and 3.65. Figure 3.63 shows the Exam 3 observed
prevalence rates from the Framingham Study have the same trend but higher level as
in the UK observed prevalence rates. For hypercholesterolaemia level 1, the observed
prevalence rates have a decreasing trend as shown in Figures 3.64, 3.65 and 3.66 for
Framingham Study Exam 1 to 6, UK data sources and UK data sources and Framing-
ham Exam 3, respectively. We can say that Exam 3 observed prevalence rates from
the Framingham Study is quite similar to the observed prevalence rates in 1980s as
shown in Figure 3.66.
Figures 3.67, 3.68 and 3.69 show the observed prevalence rates for hypercholestero-
laemia level 2 and Figures 3.70, 3.71 and 3.72 show the observed prevalence rates for
hypercholesterolaemia level 3 from Framingham Study Exam 1 to 6, UK data sources
and UK data sources and Framingham Exam 3, respectively. There is an increasing
trend in the UK observed prevalence rates as shown in Figure 3.68 which is different
from the trend in the Framingham Study observed prevalence rates. As shown in
Figure 3.67, the observed prevalence rates are decreasing over time. Observed preva-
lence rates from Exam 3 in the Framingham Study are lower than the UK observed
prevalence rates, shown in Figure 3.69 which is also true for level 3 shown in Figure
3.72.
Figures 3.73, 3.74 and 3.75 show the observed prevalence rates for hypercholestero-
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laemia level 0 for females from Framingham Study Exam 1 to 6, UK data sources and
UK data sources and Framingham Exam 3, respectively. A clear increasing trend can
be seen at older ages in the UK observed prevalence rates, shown in Figure 3.74 and
the 1981 UK observed prevalence rates do not have the same levels as the observed
prevalence rates in the same year in the Framingham study which is shown in Figure
3.75. Figures 3.76, 3.77 and 3.78 show the observed prevalence rates for hypercholes-
terolaemia level 1 and Figures 3.79, 3.80 and 3.81 show the observed prevalence rates
for hypercholesterolaemia level 2 from Framingham Study Exam 1 to 6, UK data
sources and UK data sources and Framingham Exam 3, respectively. The observed
prevalence rates from Exam 3 in the Framingham Study does not have the same level
as the observed prevalence rates in the UK 1980s observed prevalence rates for both
levels, shown in Figures 3.78 and 3.81. Figures 3.82, 3.83 and 3.84 show the observed
prevalence rates for hypercholesterolaemia level 3 for females from Framingham Study
Exam 1 to 6, UK data sources and UK data sources and Framingham Exam 3, re-
spectively. The trend over age is similar between the observed prevalence rates from
the Framingham Study and UK data sources but different levels between the observed
prevalence rates from the same year.
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Figure 3.61: Prevalence of
hypercholesterolaemia level 0 for males
in Framingham.
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Figure 3.62: Prevalence of
hypercholesterolaemia level 0 for males
in the UK.
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Figure 3.63: Prevalence of
hypercholesterolaemia level 0 for males
in the UK and Framingham.
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Figure 3.64: Prevalence of
hypercholesterolaemia level 1 for males
in Framingham.
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Figure 3.65: Prevalence of
hypercholesterolaemia level 1 for males
in the UK.
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Figure 3.66: Prevalence of
hypercholesterolaemia level 1 for males
in the UK and Framingham.
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Figure 3.67: Prevalence of
hypercholesterolaemia level 2 for males
in Framingham.
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Figure 3.68: Prevalence of
hypercholesterolaemia level 2 for males
in the UK.
10 20 30 40 50 60 70 80
0
.
0
0
.
1
0
.
2
0
.
3
0
.
4
0
.
5
Age
P
r
e
v
a
l
e
n
c
e
Exam 3
1981 rates
DNS86
HSE94
2000 rates
HSE03
Figure 3.69: Prevalence of
hypercholesterolaemia level 2 for males
in the UK and Framingham.
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Figure 3.70: Prevalence of
hypercholesterolaemia level 3 for males
in Framingham.
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Figure 3.71: Prevalence of
hypercholesterolaemia level 3 for males
in the UK.
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Figure 3.72: Prevalence of
hypercholesterolaemia level 3 for males
in the UK and Framingham.
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Figure 3.73: Prevalence of
hypercholesterolaemia level 0 for females
in Framingham.
10 20 30 40 50 60 70 80
0
.
0
0
.
2
0
.
4
0
.
6
0
.
8
1
.
0
Age
P
r
e
v
a
l
e
n
c
e
1981 rates
DNS86
HSE94
2000 rates
HSE03
Figure 3.74: Prevalence of
hypercholesterolaemia level 0 for females
in the UK.
10 20 30 40 50 60 70 80
0
.
0
0
.
2
0
.
4
0
.
6
0
.
8
1
.
0
Age
P
r
e
v
a
l
e
n
c
e
Exam 3
1981 rates
DNS86
HSE94
2000 rates
HSE03
Figure 3.75: Prevalence of
hypercholesterolaemia level 0 for females
in the UK and Framingham.
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Figure 3.76: Prevalence of
hypercholesterolaemia level 1 for females
in Framingham.
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Figure 3.77: Prevalence of
hypercholesterolaemia level 1 for females
in the UK.
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Figure 3.78: Prevalence of
hypercholesterolaemia level 1 for females
in the UK and Framingham.
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Figure 3.79: Prevalence of
hypercholesterolaemia level 2 for females
in Framingham.
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Figure 3.80: Prevalence of
hypercholesterolaemia level 2 for females
in the UK.
10 20 30 40 50 60 70 80
0
.
0
0
.
1
0
.
2
0
.
3
0
.
4
0
.
5
Age
P
r
e
v
a
l
e
n
c
e
Exam 3
1981 rates
DNS86
HSE94
2000 rates
HSE03
Figure 3.81: Prevalence of
hypercholesterolaemia level 2 for females
in the UK and Framingham.
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Figure 3.82: Prevalence of
hypercholesterolaemia level 3 for females
in Framingham.
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Figure 3.83: Prevalence of
hypercholesterolaemia level 3 for females
in the UK.
10 20 30 40 50 60 70 80
0
.
0
0
.
2
0
.
4
0
.
6
0
.
8
Age
P
r
e
v
a
l
e
n
c
e
Exam 3
1981 rates
DNS86
HSE94
2000 rates
HSE03
Figure 3.84: Prevalence of
hypercholesterolaemia level 3 for females
in the UK and Framingham.
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3.3.5 IHD, Stroke and Mortality
For IHD and stroke observed prevalence rates, we calculated the 1981 and 2000 ob-
served prevalence rates from the HSE observed prevalence rates taken from NHS
(2006). We extrapolate the HSE94 and HSE06 observed prevalence rates to get the
observed prevalence rates in 1981 and interpolate using the same HSE year observed
prevalence rates for the observed 2000 prevalence rates. We use the English Life Ta-
bles no 14 and 16 to represent the mortality rates in 1981 and 2000. Figures 3.85,
3.86 and 3.87 show the rates for IHD, stroke and IHD and/or stroke for males. The
observed prevalence rates for females are shown in Figures 3.88, 3.89 and 3.90.
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Figure 3.85: Prevalence of IHD for males
in the UK.
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Figure 3.86: Prevalence of stroke for
males in the UK.
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Figure 3.87: Prevalence of IHD and/or
stroke for males in the UK.
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Figure 3.88: Prevalence of IHD for
females in the UK.
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Figure 3.89: Prevalence of stroke for
females in the UK.
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Figure 3.90: Prevalence of IHD and/or
stroke for females in the UK.
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3.4 Summary
The observed prevalence rates are calculated from different sources to obtain the ob-
served prevalence rates for different years. The observed prevalence rates calculated
from the UK Data Archives are consistent with the trends of the observed prevalence
rates taken from the Health Survey of England except for some categories in hyper-
tension. These rates will be used as the initial risk profiles in the HW model for years
1981 and 2000 and as the observed 1981 and 2000 prevalence rates, which will be
matched by adjusting the HW model.
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Chapter 4
Sudden Death Adjustments
4.1 Introduction
Before we start adjusting the transition intensities for the risk factors, we adjust the
sudden death probabilities to match the sudden death observed rates in 1981 and
2000. In the HW Model, sudden death is defined as death from any cause within one
month following myocardial infarction (MI) or stroke. It is a significant factor to be
looked into as the crude risk of death was greatest in the first year after stroke (36%
in 1989-90 and 37% in 1995-96) and particularly in the first 30 days from onset (22%
in 1989-90 and 23% in 1995-96), according to Hardie et al. (2005), a study in Perth,
Western Australia. Caro et al. (2005) stated that 17% of patients with myocardial
infarction and 10% of patients who suffered a stroke died within the first 30 days.
Some studies define sudden death as IHD death that occured within one hour of
the onset of symptoms (e.g. Fox et al., 2004), while Volmink et al. (1998) identified
sudden death as a fatal infarction where death occured before the patient could be
seen by a doctor. We are interested to see how the probability of sudden death from
MI or stroke has changed over the period 1981–2000. We look at studies that focus
on sudden death with the same definition as for the HW Model.
4.2 Myocardial Infarction
A summary of the literature on sudden deaths following a MI is shown in Table 4.1.
Studies that we had looked into suggested that the sudden death observed rates for
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myocardial infarction in England and some other countries decreased over the period
1981–2000. The observed rates from the studies, where available, are shown in Figure
4.1 which includes the results calculated from the Framingham dataset. The studies
referenced in Table 4.1 are discussed below.
Oxford Myocardial Infarction Incidence Study (OXMIS)
The Oxford Myocardial Infarction Incidence Study Group (OXMIS), Volmink et al.
(1998), studied the sudden death observed rate for myocardial infarction among a
population of 568, 800 in Oxfordshire, England in 1994 - 95. The OXMIS study
considered the rate for overall sudden death, which is the proportion of hospitalised
patients who died within 28 days of onset of symptoms and the proportion of these
patients who died before reaching hospital (out of hospital case fatality rate). The
overall sudden death rate declined significantly by 28% in men (from 56.7% in 1966-67
to 41.0% in 1994-95) and 32% (from 64.6% in 1966-67 to 44.1% in 1994-95) in women.
The reduction in case fatality rates from hospitalised cases only are higher: for men,
there is a reduction of 43.4% (from 27.2% in 1966-67 to 15.4% in 1994-95) and for
women, the reduction is 52.7% (from 45.5% in 1966-67 to 21.5% in 1994-95). Volmink
et al. (1998) suggested that the reductions in coronary events and sudden death rates
are related to reductions in risk factors and improvements in medical care.
National Centre for Health Outcomes Development by NHS
Another useful study that shows the reduction in the rates of sudden deaths from
MI is given by the National Centre for Health Outcomes Development (NHS, 2009).
This provides a recent set of data which includes years 1999 to 2007. The National
Health Service (NHS) has calculated the indirectly standardised by age and diagnosis
rates for deaths from MI. The data consists of deaths in hospital and after discharge
within 30 days of an emergency admission to hospital with MI. All death records are
taken from the Hospital Episodes Statistics (HES 2008) and the Office for National
Statistics (ONS) from ages 35 to 74. The sudden death rates are standardised using
England 2002/2003 age, sex and diagnosis rates. 30-day death rates for women were
higher than men in both conditions, but both have shown some improvements as
shown in Figure 4.1. The 30-day death rates for MI reduced by 41% for women and
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38% for men. These data include only those who had reached hospital and do not
include sudden deaths at home without being referred to the hospital.
The Framingham Heart Study
Studies from other countries also suggest that there are reductions in sudden death
from MI. Fox et al. (2004) concluded that over the period from 1950 to 1999 the
sudden death rates in the Framingham Heart Study decreased by 49%. The risk of
sudden death for those without prior history of IHD was 39% lower in 1990 to 1999
compared to 1950 to 1969, whereas for those with a prior history, the risk was 57%
lower, comparing the same year. Reductions were also seen for smokers and non-
smokers. This study defined sudden death as death within 1 hour after symptom
persisted. There were 12 cases of participants who were resuscitated and survived for
at least 1 hour and were excluded from the above results. Including these people,
which in case of failure to resuscitate would cause them to be sudden deaths, would
lower the risk of sudden death to 38% in 1990 – 1999 compared to 1950 – 1969, which
suggested that part of the decline could be because of patients who survived as a
result of resuscitation.
Olmsted County, Minnesota
A study of trends in the incidence of coronary disease conducted in Minnesota by
Arciero et al. (2004) indicated that the age– and sex– adjusted incidence of sudden
deaths declined over time, from 23% in the 1979 – 1983 period to 17% during the 1994
– 1998 period, a reduction of 26.1%. The definition of sudden death in this study
is death that occurred out of hospital. From Table 1 in Arciero et al. (2004), the
changes between sudden deaths for men and women are not quite significant in the
second decade, between 1988-93 and 1994-98. The number of sudden deaths for men
aged less than 60 is 28 in 1988-93 and 26 in 1994-98, whereas the number of sudden
deaths in women has not changed between these years for the same age group. In
older ages (more than 80 years old), the number of sudden deaths was 60 and 58
in 1988-93 and 1994-98 respectively, while for women the number of sudden deaths
is the same between 1988-93 and 1994-98. The sudden death trend among patients
in Minnesota is the same for both men and women in the second decade, which is
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between 1988-93 and 1994-98.
Pennsylvania
However, there are some studies that reported no changes in sudden deaths from MI.
Over 21 years of study for white males, aged 35 to 44 years old in Pennsylvania,
Traven et al. (1995) reported no reduction in sudden deaths for IHD. This study
defined sudden death as death within 24 hours of the symptoms with no history of
heart disease. There was also a quite steady rate for death within one hour of onset.
The proportion of sudden deaths has not changed across the two decades despite the
reduction in the incidence of heart disease where the IHD mortality reduced by 60%
between 1970-72 and 1988-90.
Belfast
A study on temporal trends in out of hospital sudden cardiac death (OHSCD) in
Belfast by Moore et al. (2006) concluded that the incidence of OHSCD over the past
20 years has not fallen despite a 37% reduction in heart attack mortality in Ireland.
This study defined sudden death as death within one hour of symptoms.
4.2.1 Modelling Sudden Deaths Following Myocardial Infarc-
tion
We will model the probability of sudden death following a myocardial infarction
(SDMI) by using the data from the Framingham Heart Study from 1971 to 1991,
which is the Original Cohort (OC). For the Offspring and Spouses Cohort (OS), there
were missing data on the date of events of MI. Since the number of the cases of MI
in the OS data is quite small, this should not affect our model. In the Framingham
OC data, there were 179 sudden deaths following a MI from 1049 MI cases for males
and females. We will model the sudden deaths using a GLM, fitted using the R sta-
tistical package, under a binomial distribution for the number of sudden deaths. The
response variable which is the SDMI (DMI) will take the value 0 if the individual is
alive after 30 days and 1 if the individual has died within 30 days after MI. First we
model the SDMI using age at MI, year of MI and sex as the explanatory variables.
70
Name of study Period Definition of sudden death Reduction of SDMI within the given pe-
riod
Oxford Myocardial In-
farction Incidence Study
(OXMIS)
by Volmink et al. (1998)
1994 – 95
(compared with 1966 – 67)
Patients who died within 28 days of on-
set of symptoms (hospitalised and out of
hospital)
Males: 28% (56.7% to 41%)
Females: 32% (64.6% to 44.1%)
National Centre for Health
Outcomes Development
by NHS (2009)
1999 – 2007 Deaths in hospital and after discharge
within 30 daysof an emergency admission
to hospital with MI (hospitalised)
Males: 38% (10.22% to 6.35%)
Females: 41% (12.74% to 7.49%)
The Framingham Heart
Study (OC & OS)
by Fox et al. (2004)
1950 – 1999 CHD deaths that occurred within 1 hour
of the onset of symptoms (hospitalised)
Overall: 49% Males: 49%
Females: 47%
Olmsted County, Min-
nesota
by Arciero et al. (2004)
1979 – 1983
and 1994 – 1998
Deaths occured out of hospital due to
CHD
A reduction of 26.1% (23% in 1979 – 83
to 17% in 1994 – 98)
Very little change between the 2nd decade,
1988 – 93 and 1994 – 98
Pennsylvania
by Traven et al. (1995)
1970 – 1990 Deaths within 24 hours of the symptoms
(hospitalised and out of hospital)
No trends of reduction in 35 – 44 years
old white males
Out of hospital sudden
cardiac death (OHSCD)
Belfast
by Moore et al. (2006)
2004 (compared with 1966) Deaths within one hour of onset of symp-
toms
Does not appear to have fallen over the
past 38 years (1966 – 2004)
Table 4.1: Literature summary for sudden deaths following a myocardial infarction
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Figure 4.1: Rates of sudden death from myocardial infarction from Table 4.1
We found that age at MI and year of MI are significant explanatory variables while
sex is not a significant factor for modelling the SDMI. The model is shown below and
the R output is shown in Table 4.2:
DSDMI˜Bin(1, PSDMI)
where
logit(PSDMI) = b0 + b1Age+ b2Y earMI (4.1)
Coefficients Estimate Standard Error P-value
b0 36.83813 21.27982 0.0834
b1 0.06241 0.01109 1.81e-08
b2 -0.02166 0.01105 0.0499
Table 4.2: Summary of SDMI model.
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Figure 4.2 shows the probability of sudden deaths from MI from the modelling
for 3 different ages, 40, 71 and 80. We can see that the probability increases as
age increases and there are reductions over the years for all ages. The probability is
consistent with most of the literature in Table 4.1, which suggests that the sudden
death rates decreased over time. The probability of sudden death following MI from
the R output in Table 4.2 is shown below:
PSDMI =
exp(36.83813 + 0.06241× Age− 0.02166× Y ear)
1 + exp(36.83813 + 0.06241×Age− 0.02166× Y ear)
(4.2)
In Figure 4.2, we have the sudden death rates from the literature and we used the
average age at events (age 67) in the Framingham data (shown in the graph as the red
line) to compare our model. We also include the model estimated sudden death rates
for ages 40 and 80 calculated from the model. The data for the UK sudden death
rates are from the Oxfordshire Study (Volmink et al., 1998) and The National Health
Service (NHS) for males and females. The sudden death rate for the average age at
MI in the Framingham Data seems to be consistent with the NHS rates for males and
females in 1999 to 2007. Therefore, we will use this model without any adjustment.
4.3 Stroke
Table 4.3 shows a summary of some of the literature on sudden deaths following a
stroke (SDHS). Sudden death from stroke has shown no significant improvement over
time, as reported in some studies that have similar definition of SDHS with the HW
Model. SDHS is defined as sudden deaths following a stroke from hospitalised and
non–hospitalised cases within 30 days. Figure 4.3 shows the rates of SDHS from the
studies discussed below and the sudden death rates include the results calculated from
the Framingham dataset.
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Figure 4.2: SDMI model and UK age standardised rates
Oxfordshire Study
Sudden death from stroke has shown no significant improvement over time as reported
in some studies. In an Oxfordshire Study by Rothwell et al. (2004), the 30-day case-
fatality from stroke remained the same between 1981-1984 and 2002-04, where the
sudden death rates were 17.8% and 17.2% respectively, although there was a decline
of 29% in incidence of stroke.
FINSTROKE Study
In a study that analyzed the case fatality from stroke in Finland, Sivenius et al. (2004)
stated that the decrease in 28-day case fatality of stroke between 1983 and 1997 in
men is from 21.7% to 18.2%, and from 22.2% to 19.2% in women. Dividing this into
different types of stroke, case fatality of ischaemic stroke remained stable and similar
in men and women between 1988 and 1997, while case fatality of heamorrhagic stroke
decreased slightly in men and significantly in women, from 55.2% to 32.6%.
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National Centre for Health Outcomes Development by NHS
The latest data (1999 to 2007) from The National Health Service (NHS, 2010) has
shown some reductions in sudden deaths from stroke. The NHS has calculated rates
of deaths from stroke the indirectly standardised by age and diagnosis. The data
are the same as the data for MI, where it is deaths after admission to hospital or
after discharge within 30 days. Figure 4.3 shows the trend of SDHS from 1999 to
2007 for men and women. Between these years, the probability of deaths within 30
days for stroke seems to be declining. Deaths within 30 days declined by 27.5% and
21% for men and women, respectively. Comparing it with the study by Rothwell
et al. (2004) which showed no significant reduction between 1981-1984 and 2002-04,
the reduction shown in these data might indicate that within recent years there may
has been an improvement in treatment, as people who have strokes are more likely
to survive if admitted quickly to a hospital with treatment and care provided by a
specialist coordinated stroke team. Also, the NHS data relates to 1999 to 2007, which
does not overlap with the period that we are interested in.
NHS Scotland Study
A study of stroke in Scotland by Lewsey et al. (2009) concluded that short-term case
fatality for stroke is greater in women than men over the 20 – year period of study,
from 1986 to 2005. From Lewsey et al. (2009), there was a reduction in the short-term
case fatality especially for men and women less than 55 years old. This study also
has a declining trend and the short-term case fatality only includes hospitalised cases,
which is similar to NHS (2010).
4.3.1 Modelling Sudden Deaths Following Stroke
We will model the probability of sudden deaths following a stroke by using the same
dataset and methods as used in Section 4.2.1. We will use the Framingham dataset,
which includes 157 cases of sudden deaths following a stroke from 740 stroke cases for
males and females. We start the modelling by including age at stroke, year of stroke
and sex as the explanatory variables. However, year of stroke and sex were found to
be not significant for SDHS. This can also be seen in Figure 4.4 where we can see
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Name of study Period Definition of sudden death Reduction of SDHS within the given period
Oxfordshire Study
by Rothwell et al. (2004)
1981 – 2004 30 - day case fatality (hospitalised and out
of hospital)
Remained the same, 17.8% in 1981 – 84 and
17.2% in 2002 – 04
The FINSTROKE Study
by Sivenius et al. (2004)
1983 – 1997 28 - day case fatality Males: 21.7% to 18.2%
Females: 22.2% to 19.2%
Notes: Decline were seen in the case fatality of
heamorrhagic strokes, whereas case fatality of is-
chemic strokes did not change.
National Centre for Health
Outcomes Development
by NHS (2010)
1999 – 2007 Deaths in hospital and after discharge
within 30 days of an emergency admission
to hospital with stroke
Males: 29.4% to 21.2%
Reduction of 27.5%
Females: 30.5% to 24%
Reduction of 21%
NHS Scotland
by Lewsey et al. (2009)
1986 – 2005 30 – day case fatality (hospitalised) < 55 years old
Males: 22.7% in 1986 to 11.7% in 2005
Females: 28.4% in 1986 to 12.7% in 2005
> 85 years old
Males: 41% in 1986 to 32% in 2005
Females: 37.3% in 1986 to 31.8% in 2005
Table 4.3: Literature summary for sudden deaths following a stroke
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Figure 4.3: Rates of sudden death from stroke from Table 4.3
that the sudden death rates for different ages are almost the same over the years.
This means that there is no calendar time effect in the sudden death rates following a
stroke which is consistent with the literature in Table 4.3 that shows no improvement
over time. The model is shown below and the R output is shown in Table 4.4:
DSDHS˜Bin(1, PSDHS)
where
logit(PSDHS) = b0 + b1Age (4.3)
Coefficients Estimate Standard Error P-value
b0 -3.625166 0.651198 2.59e-08
b1 0.032011 0.008797 0.000274
Table 4.4: Summary of SDHS model.
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As year of event is not a significant factor, our model for the sudden deaths from
stroke uses only age, which can be referred to Table 4.4 and is shown below:
PSDHS =
exp(−3.625166 + 0.032011× Age)
1 + exp(−3.625166 + 0.032011×Age)
(4.4)
We compared our model with the rates of sudden death following a stroke from
the studies in Table 4.3 and this is shown in Figure 4.4. From the plot, we see that
the NHS sudden death rates are not in line with the sudden death rates from our
model, or with the Oxfordshire and Finstroke studies. The NHS Scotland includes
hospitalised and all discharges data which is similar to the NHS England data. Both
NHS rates have shown that there were reductions over time for the sudden death
rates from stroke whereas data from Oxfordshire and Finstroke show that there was
no time trend.
We note that the Oxfordshire and Finstroke studies use a definition of SDHS
consistent with our data from the Framingham Heart Study which includes all deaths
(hospitalised and out of hospital) and the results from these studies show no calendar
time effect. So we can use this model without any adjustment to match with the
UK observed rates. Power (2004) mentioned in his article that approximately 20%
of patients will die within 30 days of stroke onset in the UK. This is consistent with
our result in Figure 4.4, where the purple line shows the sudden death rates from an
average age at stroke using our model at approximately 20%.
4.3.2 Incidence of sudden death following stroke
A possible explanation for the reason why the rate of sudden death from stroke in the
NHS England and NHS Scotland data decreased over time can be given by looking
at the incidence rate for stroke over the populations. We will look at the incidence
rate per 100,000 people which is available for the NHS and Oxfordshire studies and
see what makes the trend in sudden death different between the studies. We would
expect the incidence rate from the NHS data to be lower than in the Oxfordshire
Study as the NHS only includes those who were hospitalised. Tables 4.5 and 4.6 show
the incidence rate of stroke per 100,000 people for males and females from the NHS
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Figure 4.4: SDHS model and UK age standardised rates
and Oxfordshire studies. From the tables, we can see that indeed the incidence rates
for the NHS are generally lower than for Oxfordshire.
The higher sudden death rates in the Oxfordshire study could represent the out-
of-hospital cases which might explain why there were no changes over time for sudden
death. The number of out of hospital cases in the Oxfordshire study would result
in more sudden deaths compared to the NHS. So the reduction in the sudden death
rates from hospitalised cases has been cancelled out by the out of hospital sudden
death cases which probably resulted in no changes over time in sudden death rates in
Oxfordshire and Finstroke.
Rothwell et.al (2004) stated that the incidence of stroke fell by 29% between 1981-
84 and 2002-04 (from 2.27 to 1.62 per 1000 population). This can be seen in Tables 4.5
and 4.6 by comparing the incidence rates between 1983 and 2004 in the Oxfordshire
sudden death rates. Rothwell et.al (2004) also mentioned that the decline resulted
from the increased use of preventive treatment and better control of vascular risk
factors. The decline is consistent with the reduction in mortality due to stroke in the
absence of the reduction of sudden death.
A population-based study by Kleindorfer et.al (2006) in the United States men-
tioned that the annual incidence of hospitalised stroke did not change significantly
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between 1993-94 and 1999. The incidence rate in both periods, 1993-94 and 1999 was
158 per 100,000 people. Kleindorfer et.al (2006) also measures the out-of-hospital
incidence rate and there was a slight increase over the study period, from 186 to 206
per 100,000. The 30-day sudden death rates from this study were consistent with
the Oxfordshire study where there were no significant changes over time. The 30-day
sudden death rates in 1993-94 and 1999 were 13.9% and 14.7%, respectively. These
rates include the hospitalised and out of hospital cases.
Using the England NHS data and estimated population data from the ONS, we
calculated the age-standardised sudden death rates per 100,000 people from 1999 to
2008 for males and females. These are shown in Table 4.7. There is a slight decrease
in the incidence of stroke over the time period. The NHS data includes all ages so
we compared the sudden death rates with the Oxfordshire sudden death rate for all
age groups. In 2004, the Oxfordshire sudden death rate per 100,000 population for
all ages was 134 for males and 156 for females which is shown in Table 1 in Rothwell
et.al (2004). Comparing these rates with the NHS sudden death rates in the same
year, the NHS rates were lower than the Oxfordshire sudden death rates, 127 and 138
for males and females, respectively.
There were no changes in sudden death rates over time although there were changes
in the incidence of stroke, as mentioned in the Oxfordshire study. As expected, the
sudden death rate for studies that includes hospitalised and out of hospital cases are
higher than hospitalised only cases. The risk of sudden death from stroke is higher for
those who have not been admitted to hospital so this may cause the rate of sudden
death to remain the same.
Age NHS Scotland Oxfordshire
1985 2005 1983 2004
55-64 250 250 368 214
65-74 500 450 819 678
75-84 1250 900 1772 1085
85+ 1900 1300 1994 2063
Table 4.5: Incidence rate of stroke per 100,000 populations for males
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Age NHS Scotland Oxfordshire
1985 2005 1983 2004
55-64 200 200 181 140
65-74 450 300 601 464
75-84 1000 750 1529 1109
85+ 1600 1250 1769 1863
Table 4.6: Incidence rate of stroke per 100,000 populations for females
Year Males Females
1999 140 151
2000 134 147
2001 129 141
2002 130 139
2003 130 141
2004 127 138
2005 123 133
2006 121 130
2007 116 123
2008 115 119
Table 4.7: NHS incidence rate of stroke per 100,000 population for males and females
4.4 Summary
Tables 4.1 and 4.3 show a summary of several studies on sudden deaths from MI
and stroke. There are more improvements in sudden deaths from MI compared to
stroke. Reductions in sudden death in MI can be seen from studies in England and
Framingham. Sudden death from stroke has not shown significant improvements, as
mentioned in the Oxfordshire and Finland studies, but there are improvements since
1999 as shown in the NHS data. We have modelled the changes over time of sudden
death in MI and stroke and built it in the HWModel. The adjustments for probability
of sudden deaths following a MI is a function of age and year of MI, while for stroke
it is a function of age only. The adjustments will be included in the HW Model in
which the intensities for other risk factors will be adjusted to match the 1981 and
2000 observed rates. The probability of sudden deaths following a MI and a stroke
will be added to the mortality rates. The probability is added to the mortality rates
to assume deaths happen to new cases of MI and stroke within 30 days of the attack,
thus adjusting the mortality rates.
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Chapter 5
Adjustments to Other Risk Factors
5.1 Introduction
Further adjustments are needed to other risk factor intensities to match the model
with 1981 and 2000 observed prevalence rates (taken from data and surveys) and
here we include the sudden deaths adjustments to the HW Model as explained in the
previous chapter. The risk profiles calculated from Tables 3.7 and 3.8 are put into
the HW Model as the 1961 and 1981 initial risk profiles as mentioned in Section 2.3
and we run it for 19 and 20 years to get the HW Model estimated prevalence rates in
1981 and 2000. We will make adjustments to the risk factors based on the sequence
of the significant risk factors table given in the HW Model (Chatterjee et al., 2008a,
Table 12).
Figure 5.1 is a diagram that shows how each risk factor influences other risk
factors based on Table 12 in Chatterjee et al. (2008a). As mentioned in Chatterjee
et al. (2008a), an obvious feature is that BMI is a significant explanatory factor for
hypertension, diabetes transition from level 0 to 1 and mortality. This is graphically
demonstrated in Figure 5.1 where changes in BMI affect hypertension, diabetes and
mortality. Hypercholesterolaemia is a significant risk factor for mortality, IHD and
stroke, as also illustrated in Figure 5.1. In Table 12 (Chatterjee et al., 2008a), only
age and sex affect significantly the changes in hypercholesterolaemia.
Based on Chatterjee et al. (2008a), we also observed the following significant
effects. After age and sex, smoking is also a significant factor for transition between
BMI categories, particularly for category 2 to 1, 1 to 2 and 2 to 3. Smoking is also
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Figure 5.1: Diagram of the sequence of significant risk factors.
a significant factor that increases the risk of having IHD and stroke. BMI is then
a significant factor for diabetes and hypertension. Age and sex are the significant
risk factors for hypercholesterolaemia so any adjustments to other risk factors will
not affect the transition between the categories of hypercholesterolaemia. All the risk
factors then affect the prevalence rates of IHD, stroke and mortality.
We have applied some adjustment for the modelling of sudden death following
IHD and stroke in the previous section as sudden death is dependent on age and year
of event and is not influenced by the risk factors in the diagram. This is based on
Chatterjee et al. (2008a, Section 9.3) where they used the Framingham data to model
probabilities of sudden death from MI and HS and included all risk factors in their
model but found only age was the significant factor for MI and that no risk factors
were significant for HS. Since smoking is a deterministic factor and will influence some
categories of BMI and indirectly influence diabetes and hypertension, we choose to
start with the smoking factor. The definition of each risk factor is shown in Tables
2.1, 2.2, 3.5 and 3.6.
5.2 Adjustments to model intensities
We will start our adjustments with the HW Model transition intensities and include
the adjustment for sudden death as mentioned in Chapter 4. First we will make
adjustments by changing the transition intensities in the HW Model to match the
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observed prevalence rates in 2000 and then we will obtain another set of intensities to
match the observed prevalence rates in 1981. The adjustments will be done based on
the following sequence: smoking, BMI, diabetes, hypertension, hypercholesterolaemia,
IHD, stroke and mortality. These intensities are adjusted by hand as mentioned in
Section 2.2. Using the results from the adjusted model, we calculate the prevalence
rates of different levels of each risk factor for surviving males and females by using
this calculation:
Px|G,SP (ib) =
fHWx,x−t(ib | P
indY ear
x−t (I), G, SP )
(1− fHWx,x−t(Dead | P indY earx−t (I), G, SP ))
(5.1)
where
Px|G,SP (ib): the probability of being in state ib at age x for a given sex, G and
smoking profile, SP ,
fHWx,x−t(ib | P
indY ear
x−t (I), G, SP ): the probability of being in state ib at age x for
a given sex, G, smoking profile, SP , and a given initial risk profile, P indY earx−t (I)
at age x− t,
fHWx,x−t(Dead | P
indY ear
x−t (I), G, SP ): the probability of being dead at age x for a
given sex, G, smoking profile, SP , and a given initial risk profile, P indY earx−t (I)
at age x− t,
Y ear: year for the independent initial risk profiles, 1961 or 1981,
t: 20 if Y ear is 1961 and 19 if Y ear is 1981.
5.2.1 Confidence intervals for observed prevalence rates
As mentioned in Section 5.2, adjustments will be informed by quantifying the un-
certainty in the observed prevalence rates, and therefore we provide relevant 95%
confidence intervals for each of these observed prevalence rates. We note here that, as
mentioned in Section 2.5, observed prevalence rates are taken from the Health Sur-
vey for England (HSE, 2006) which provides figures for the proportion of the general
population, in specified age groups, with a risk factor at a specific level (where appro-
priate). It also provides the number of people sampled in each group. The numbers
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provided in HSE (2006) only concern individual risk factors, ignoring joint prevalence
of one or more of these factors. For this reason, and also for simplifying the calculation
of the confidence intervals, we only consider here risk factors separately. Therefore,
taking different age groups as the sampled populations under consideration, this leads
to a binomial assumption for the number of people with a risk factor of two category
levels, such as diabetes, IHD and stroke (and for mortality). Following the usual
assumptions of independence and common probability of occurrence among subjects,
95% confidence intervals are then calculated using the common normal approximation
to the binomial distribution, which gives:
pˆ± Z(α/2)
√
pˆ(1− pˆ)
n
(5.2)
= pˆ± 1.96
√
pˆ(1− pˆ)
n
(5.3)
where pˆ is the sample proportion of the specified age group with the risk factor and n
is the relevant sample size. Similarly, for risk factors with more than 2 category lev-
els, such as BMI, hypertension and hypercholesterolaemia, we assume a multinomial
distribution and use a similar normal approximation (Goodman, 1965), giving:
pˆi ± Z(α/2k)
√
pˆi(1− pˆi)
n
(5.4)
where pˆi, i = 1,. . . , k is the sample proportion with level i of the risk factor, and k is
the number of risk factor levels. For all figures in this chapter, the total populations
are the total population in the age groups explained below:
Age group 1: 44 - 54,
Age group 2: 55 - 64,
Age group 3: 65 - 74,
Age group 4: 75 - 84.
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5.3 Adjusted prevalence rates for 2000
In this section we provide adjusted prevalence rates for 2000, which are derived as
described in Section 5.2.
5.3.1 Smoking
Smoking is a deterministic factor in the HW Model so we will determine the patterns
of smoking in the population based on the available data from the General Household
Survey 2006 (Goddard, 2006) and we will have different scenarios to be applied to the
model. The smoking scenarios are explained below:
(i) Never smoked
This group consists of non–smokers who never smoke throughout their lifetime.
(ii) Smokers
This group started smoking at ages shown in Table 5.1 and smoke throughout
their lifetime. Specifically Table 5.1 shows the percentages of people who started
smoking regularly at different ages in 2000 for males and females from Goddard
(2006). From the table, we can see that many smokers started to smoke before
age 16, so we assumed that people who smoke have started smoking at the age
of 15.
(iii) Ex-smokers
For ex-smokers, we assumed that they have started smoking at the age of 15
and gave up smoking between 1980 and 2000. We assumed that the smokers
quit smoking uniformly between the two years of reference, so that the middle
of the interval (1990) is taken as the time of quitting.
We will run the HW Model based on different smoking scenarios and include the
adjustment for sudden deaths, as explained in the previous chapter. The prevalence
rates for each smoking scenario are weighted by the smoking prevalence for England
and Wales populations in 2000 from the Office for National Statistics (ONS), as shown
in Tables 3.2, 3.3 and 3.4. These give the estimated prevalence of the risk factors for
86
Age group % of Male % of Female
under 16 43 33
16 - 17 27 27
18 - 19 15 19
20 - 24 11 12
25+ 5 8
Table 5.1: Age started smoking regularly in 2000, by sex.
each category in 2000. As we have determined the smoking scenario, we will calculate
the prevalence of different categories of BMI in 2000 using the model and compare it
with the observed prevalence rates.
5.3.2 BMI
Using the 1981 independent risk profiles, we run the HW Model by projecting forward
for 19 years to get the HW model estimated prevalence rates in 2000. The prevalence
rates for different smoking scenarios are then weighted by the smoking prevalence,
as mentioned in the previous section. The BMI model that we used is Model 1 in
Chatterjee et al., (2008b) which does not allow for changes in the prevalence of obesity
over calendar time.
Figures 5.2, 5.3, 5.4, 5.5 and 5.6 show the comparison between the HW model
estimated prevalence rates before and after adjustments and the observed prevalence
rates for each category of BMI for males for each age group. From the graphs, the
prevalence rates from the model before adjustments for BMI levels 0, 2 and 4 in Figures
5.2, 5.4 and 5.6 are similar to the observed prevalence rates and lie within the 95%
confidence limits of the observed prevalence rates whereas from Figures 5.3 and 5.5 for
males, we can see that the HW model estimated prevalence rates before adjustment
from the HW Model are significantly different from the observed prevalence rates.
The trend over age is almost the same as for the observed prevalence rates for all
levels. In Figure 5.3, the estimated prevalence rates from the HW Model are higher
than the observed prevalence rates whereas in Figure 5.5, the HW model estimated
prevalence rates are lower than the observed prevalence rates. So we need to adjust
the forward and backward transition from levels 2 and 3, mostly at the intercepts.
The adjustments that were made to the BMI transition intensities are shown in
Table 5.2. The changes shown in the table are the changes in the coefficient of the
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variables stated in the table. The estimated prevalence rates from the HW Model
after adjustments are shown in Figures 5.2 to 5.6. We can see that after adjustments,
the HW model estimated prevalence rates lie within the confidence intervals of the
observed prevalence rates.
Transition Variables
Changes
From To
BMI01 intercept −2.0093 −2.0393
BMI12
intercept −2.5725 −2.3625
age2 −0.000075 −0.000025
BMI23 intercept −3.3188 −2.9788
BMI21 intercept −3.9435 −3.9735
BMI10 intercept −7.5065 −7.0065
Table 5.2: Adjustments in BMI intensities for males.
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Figure 5.2: Prevalence of BMI level 0 in
2000 (males).
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Figure 5.3: Prevalence of BMI level 1 in
2000 (males).
Figures 5.7, 5.8, 5.9, 5.10 and 5.11 show the comparison for females. The adjust-
ments for females involved all levels. The adjustments made are listed in Table 5.3.
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Figure 5.4: Prevalence of BMI level 2 in
2000 (males).
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Figure 5.5: Prevalence of BMI level 3 in
2000 (males).
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Figure 5.6: Prevalence of BMI level 4 in
2000 (males).
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Figure 5.7: Prevalence of BMI level 0 in
2000 (females).
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Figure 5.8: Prevalence of BMI level 1 in
2000 (females).
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Figure 5.9: Prevalence of BMI level 2 in
2000 (females).
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Figure 5.10: Prevalence of BMI level 3 in
2000 (females).
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Figure 5.11: Prevalence of BMI level 4 in
2000 (females).
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The trend over age group for levels 1, 2 and 3 is the same as for the observed preva-
lence rates but not for level 4. We added an age2 term to some of the transitions to
adjust the model. More adjustments were made to females compared to males. The
HW model estimated prevalence rates are shown in Figures 5.7 to 5.11 and we can
see that the model estimated prevalence rates lie within the 95% confidence limits for
the observed prevalence rates.
Transition Variables
Changes
From To
BMI01 intercept −2.0093 −1.7093
BMI12
intercept −2.5725 −2.2225
age2 −0.000075 −0.000055
intercept female −1.3913 −1.3992
intercept female ex−smoker −3.4373 −3.4073
age female 0.02196 0.04996
age2 female 0.000025 0.000005
BMI23
intercept −3.3188 −2.4488
age2 −0.000075 −0.000055
intercept female 0.5096 0.3296
age2 female 0.000025 0.000005
BMI34
intercept female 1.7403 2.4903
add age female −0.02525
BMI43 intercept −3.035 −2.611
BMI32
intercept −3.5036 −2.1636
add age −0.007
add age2 0.0001
BMI21
intercept female 0.2572 2.19
add age −0.007
add age2 0.0003
BMI10
intercept −7.5065 −7.0065
intercept female 1.5701 1.5901
Table 5.3: Adjustments in BMI intensities for females.
5.3.3 Diabetes
We then run the HW Model by including the previous adjustments. We made one
adjustment to the diabetes intensities for males to get the HW model estimated
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prevalence rates to be within the confidence interval for the observed prevalence rates.
The observed prevalence rates are shown in Figures 3.32 and 3.35 for males and
females. We adjusted the transition for diabetes from level 0 to 1 (DIAB01) for the
intercept, from −13.1194 to −13.2194 to reduce the transition from level 0 to 1. The
diabetes estimated rates from the HW model after the BMI adjustments and before
any further adjustments were made are shown in Figure 5.12 for males. The HW
model estimated prevalence rates after adjustment and the 2000 observed prevalence
rates for males are also shown in the same figure.
For females, the transition from 0 to 1 is adjusted by increasing the intercept. The
coefficients for age and age2 are also adjusted to increase the estimated prevalence
rates over age and at older ages as shown in Figure 5.13. The adjustments are shown in
Table 5.4 and the HW model estimated prevalence rates are shown in Figure 5.13. By
looking at the minimal adjustments for diabetes, it can be said that the adjustments
for BMI have affected the estimated prevalence rates for diabetes and this shows the
relationship between the changes in diabetes with BMI.
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Figure 5.12: Prevalence of diabetes in
2000 (males).
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Figure 5.13: Prevalence of diabetes in
2000 (females).
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Transition Variables
Changes
From To
DIAB10
intercept −5.7628 −4.4628
age 0.08451 0.07451
age2 −0.00007309 −0.00006809
Table 5.4: Adjustments in diabetes intensities for females.
5.3.4 Hypertension
The adjustments are continued with the hypertension risk factor. The 2000 observed
prevalence rates are shown in Figures 3.38, 3.41, 3.44 and 3.47 for males and 3.50, 3.53,
3.56 and 3.59 for females. The trend over age group from the estimated prevalence
rates for all hypertension levels is the same as in observed prevalence rates as shown
in Figures 5.14 to 5.17 so we only need to adjust by reducing the transition intensities
between the levels. Adjustments for males are shown in Table 5.5. The estimated
prevalence rates after adjustments are shown in the same figures as the observed
prevalence rates.
For females, more adjustments were made compared to males. The HW model
estimated prevalence rates before adjustments are shown in Figures 5.18 to 5.21. From
Figures 5.18, 5.19 and 5.20, we can see that levels 0, 1 and 2 are different from the
observed prevalence rates. The HW Model estimated a higher rate of hypertension
level 0 for younger ages for females in 2000 and it decreased steeply against age.
This is not the case for the observed prevalence rates as the rate for level 0 decreases
slightly with age. The Health Survey for England 2003 (Sproston & Primatesta, 2004)
reported that the prevalence of hypertension (level 1, 2 and 3) increased steeply with
age for both males and females. This leads to a slight decrease in hypertension level
0 as we can see in the observed prevalence rates in Figure 5.18. The model estimates
that a lower percentage of younger people (ages 40 and 50) in 2000 have hypertension.
This could be because the model has estimated lower obesity rates at younger ages
and this has reduced the hypertension rates for the same group as BMI levels could
effect hypertension rates. Mokdad et al. (2003) reported that those with BMI greater
than 30 (level 3 and 4) were found to have a higher risk for diabetes and hypertension
with age-adjusted odds-ratio of 3.66 and 3.72, respectively, compared to those with
normal BMI.
The adjustments for the transition intensities for hypertension for females are
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shown in Table 5.6. The adjustments were made to the transitions between all levels
of hypertension, mostly to the intercepts and age2. We also add an age2 term to
HTEN32, HTEN21 and HTEN10 to make adjustments for older ages. The HW model
estimated prevalence rates after adjustments are shown in Figures 5.18 to 5.21.
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Figure 5.14: Prevalence of h’ten level 0 in
2000 (males).
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Figure 5.15: Prevalence of h’ten level 1 in
2000 (males).
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Figure 5.16: Prevalence of h’ten level 2 in
2000 (males).
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Figure 5.17: Prevalence of h’ten level 3 in
2000 (males).
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Transition Variables
Changes
From To
HTEN23 intercept −6.107 −5.807
HTEN21 intercept −1.5793 −1.3793
Table 5.5: Adjustments in h’ten intensities for males.
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Figure 5.18: Prevalence of h’ten level 0 in
2000 (females).
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Figure 5.19: Prevalence of h’ten level 1 in
2000 (females).
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Figure 5.20: Prevalence of h’ten level 2 in
2000 (females).
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Figure 5.21: Prevalence of h’ten level 3 in
2000 (females).
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Transition Variables
Changes
From To
HTEN01
intercept female −2.2040 6.6956
age female 0.06351 −0.07454
age2 female −0.0004287 0.0006254
HTEN12
intercept female −0.1456 1.8886
age2 female 0.00006362 0.0007594
add age female −0.06396
HTEN23
intercept female 0.1204 −3.30396
add age female −0.06978
add age2 female −0.001118
HTEN32
intercept −1.4509 −2.2745
age −0.00757 0.004882
add age2 0.0000754
HTEN21
intercept −1.5793 1.3806
age −0.01088 −0.03879
add age2 −0.0000006
HTEN10
intercept female 0.3378 2.4998
age2 female −0.00008308 −0.0000129
add age female −0.0000129
Table 5.6: Adjustments in h’ten intensities for females.
5.3.5 Hypercholesterolaemia
For hypercholesterolaemia, more adjustments need to be made, compared to BMI,
diabetes and hypertension, as hypercholesterolamia is not related to changes in any
of these factors. For levels 0 and 3, the modelled trend over age is different than the
actual trend as shown in Figures 5.22 and 5.25. The HW model estimated prevalence
rates for level 1 in Figure 5.23 are higher than the observed prevalence rates whereas
for level 2 in Figure 5.24, the model estimated prevalence rates are lower than the
observed prevalence rates. We need to change the coefficients for age and age2 to
adjust the trend. We also need to adjust the intercepts to match the model estimated
prevalence rates with the observed prevalence rates. The adjustments for transitions
between categories of hypercholesterolaemia are shown in Table 5.7. The estimated
prevalence rates from the HW model are shown in Figures 5.22 to 5.25.
For females, the HW model estimated prevalence rates before any adjustments of
the transition intensities for hypercholesterolaemia are shown in Figures 5.26 to 5.29.
Hypercholesterolaemia levels 0 and 3, shown in Figures 5.26 and 5.29 respectively,
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have similar trends but need some adjustments to the model estimated prevalence
rates. The adjustments are shown in Table 5.8. Adjustments are made to the tran-
sitions between all levels of hypercholesterolaemia. These involve mainly changes to
the intercept and age2 to increase or decrease the model estimated prevalence rates
and some adjustments to the coefficients for age to adjust the trends. The model
estimated prevalence rates after adjustments are shown in the same figures as the
model estimated prevalence rates before adjustments.
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Figure 5.22: Prevalence of h’chol level 0
in 2000 (males).
Age group
Pr
ev
a
le
nc
e 
R
at
e
50 60 70 80
0.
0
0.
1
0.
2
0.
3
0.
4
0.
5
Model before adj
Model after adj
Actual with 95% CI
Figure 5.23: Prevalence of h’chol level 1
in 2000 (males).
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Figure 5.24: Prevalence of h’chol level 2
in 2000 (males).
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Figure 5.25: Prevalence of h’chol level 3
in 2000 (males).
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Transition Variables
Changes
From To
HCHOL01
intercept −5.6141 −0.8141
age −1.699 0.0005
age2 −0.001643 −0.0000000001
HCHOL12
intercept −4.9372 −0.5372
age 0.1109 0.0059
age2 −0.001279 −0.001079
HCHOL23
intercept −4.0056 −0.0056
age 0.1305 −0.035
HCHOL32 intercept −3.2804 −5.1804
HCHOL21
intercept −3.5572 −4.0572
age2 −0.0004721 −0.0007821
HCHOL10
intercept −5.2261 −1.1261
age 0.09142 0.01842
age2 −0.0007403 −0.0002403
Table 5.7: Adjustments in h’chol intensities for males.
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Figure 5.26: Prevalence of h’chol level 0
in 2000 (females).
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Figure 5.27: Prevalence of h’chol level 1
in 2000 (females).
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Figure 5.28: Prevalence of h’chol level 2
in 2000 (females).
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Figure 5.29: Prevalence of h’chol level 3
in 2000 (females).
Transition Variables
Changes
From To
HCHOL01
intercept female −0.7676 3.3207
age female 0.0147 −0.1528
age2 female −0.0000375 0.001638
HCHOL12
intercept female −3.0015 2.6730
age female 0.062 −0.08472
age2 female −0.0000411 0.0011035
HCHOL23 intercept female −1.3449 −9.8716
HCHOL32 intercept female −0.4248 −0.0158
HCHOL21
intercept female −0.2666 1.61003
add age female −0.08474
add age2 female 0.0009442
HCHOL10
intercept female 2.9518 6.1203
age female −0.1051 −0.1765
age2 female 0.0008393 0.0013596
Table 5.8: Adjustments in h’chol intensities for females.
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5.3.6 IHD, stroke and IHD and/or stroke
After some adjustments were made in the transition intensities for four risk factors,
we look into the prevalence of IHD, stroke and IHD and/or stroke. As we can see in
Figures 5.30, 5.31 and 5.32, the estimated prevalence rates for males from the HW
model are within the confidence intervals of the observed prevalence rates except for
the prevalence of IHD and/or stroke. Some adjustments were made and are shown in
Table 5.9. We adjust the parameter for age2 in angina pectoris (AP) and transient
ischemic attack (TIA) to lower the prevalence at older ages in IHD and/or stroke. We
also adjust the intercept and age parameters. The prevalences after adjustments are
also shown in Figures 5.30, 5.31 and 5.32.
Adjustments for IHD, stroke and IHD and/or stroke intensities for females are
shown in Table 5.10. There is only one transition that is adjusted, since as we can
see in Figures 5.33, 5.34 and 5.35, the model estimated prevalence rates before any
adjustments to the intensities are close to the observed prevalence rates in 2000.
Adjustments are made to the transition to MI by changing the intercept and coefficient
for age. The estimated prevalence rates after adjustments from the HW Model are
also shown in Figures 5.33, 5.34 and 5.35.
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Figure 5.30: Prevalence of IHD in 2000
(males).
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Figure 5.31: Prevalence of stroke in 2000
(males).
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Figure 5.32: Prevalence of IHD and/or
stroke in 2000 (males).
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Figure 5.33: Prevalence of IHD in 2000
(females).
Transition Variables
Changes
From To
MI
intercept −10.8973 −1.8973
age 0.06967 −0.48567
AP
intercept −15.83 −16.07
age 0.3003 0.3073
age2 0.002252 0.002203
CI age 0.04473 0.02273
TIA
intercept −21.18 −21.58
age 0.3201 0.3901
age2 −0.001708 −0.002908
Table 5.9: Adjustments in IHD, stroke and IHD and/or stroke intensities for males.
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Figure 5.34: Prevalence of stroke in 2000
(females).
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Figure 5.35: Prevalence of IHD and/or
stroke in 2000 (females).
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Transition Variables
Changes
From To
MI
intercept −10.8973 −11.0973
age 0.06967 0.07967
Table 5.10: Adjustments in IHD, stroke and IHD and/or stroke intensities for
females.
5.3.7 Mortality
We run the HW Model with all the adjustments performed earlier for eight factors
including sudden deaths and calculate the estimated mortality rates in 2000. The
model estimated rates are compared with the rates from ELT16 (ONS, 2009), the
English Life Table No 16 which covers years from the middle of 2000 to mid 2002.
The HW model estimated rates are shown in Figures 5.36 and 5.37. As shown, the
estimated mortality rates from the HW Model are within the confidence intervals of
the observed mortality rates from ELT16 and these are achieved without any adjust-
ment to the mortality intensities. The confidence intervals are calculated using the
number of exposed to risk given in the ELT16 methodology (ONS, 2009) as the sam-
ple size, n. As the previous risk factors mentioned have an effect on mortality, the
adjusted intensities might have influenced the mortality intensities so that no further
adjustment is needed.
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Figure 5.36: Mortality rates in 2000
(males).
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Figure 5.37: Mortality rates in 2000
(females).
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5.4 Adjusted prevalence rates for 1981
Having parameterised a model that matches the 2000 observed prevalence rates (HW
Model estimated 2000 prevalence rates), we then make adjustments to find a pa-
rameterisation that match the 1981 observed prevalence rates. We would need the
HW model estimated prevalence rates to be used to find the effect of changes in risk
factors between 2000 and 1981. We will use the parameters that matches the 1981
observed prevalence rates with the model that matches the 2000 observed prevalence
rates in order to quantify the changes. The 1981 observed prevalence rates are shown
in Chapter 3. We use the risk profiles for 1961 (see Table 3.7) as our starting point
and then run the model for 20 years to calculate prevalences for different age groups
as at 1981.
5.4.1 Smoking
We use the same smoking scenarios as explained in Section 5.3.1. The estimated
prevalence rates from the model are weighted using the 1981 smoking prevalence
which is calculated using interpolation with the available observed prevalence rates
from ONS. The observed prevalence rates are shown in Tables 3.2, 3.3 and 3.4 for
males and females.
5.4.2 BMI
For BMI, we adjust the original (2003) intensities to match the 1981 observed preva-
lence rates. The 1981 observed prevalence rates are interpolated between observed
prevalence rates from HWS80 and HALS84 as mentioned in Section 3.3. The observed
prevalence rates are shown in Figures 3.2, 3.5, 3.8, 3.11 and 3.2 for males and Figures
3.17, 3.20, 3.23, 3.26 and 3.17 for females. Table 5.11 shows the adjustments that
were made to the BMI transition intensities for males. The HW model estimated
prevalence rates after adjustments are shown in Figures 5.38 to 5.42. The HW model
estimated prevalence rates are adjusted to be within the 95% confidence interval of
the observed prevalence rates as shown in the figures.
For females, the adjustments are shown in Table 5.12. The adjustments are fewer
than for males as we started the adjustments by using the 1981 adjusted intensities
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for males. The HW model estimated prevalence rates are shown in Figures 5.43 to
5.47.
Transition Variables
Changes
From To
BMI01
intercept −2.0093 −1.3093
add age 0.011948
add age2 −55.002855
BMI12
intercept −2.5725 −1.9734
add age −0.611948
delete age2
BMI23
intercept −3.3188 −2.4718
age −0.00425 0.00875
delete age2
BMI34
intercept −5.9188 −8.4188
add age 0.08275
add age2 2.104805
BMI32
intercept −3.5036 −1.5636
add age 0.613
add age2 1.7561
BMI21
intercept −3.9435 −2.9735
add age 0.413
BMI10
intercept −7.5065 −5.1065
add age 0.08275
add age2 2.104805
Table 5.11: Adjustments in BMI intensities for males.
5.4.3 Diabetes
For diabetes, we have data from the Health and Lifestyle Survey 1984-1985 (HALS84)
and HSE1991 and we extrapolate the 1981 observed prevalence rates using these ob-
served prevalence rates from HALS84 and HSE1991. The observed prevalence rates
are shown in Figures 3.32 and 3.35. We adjust the intensities to match the extrapo-
lated observed prevalence rates that we have calculated before. The adjustments for
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Figure 5.38: Prevalence of BMI level 0 in
1981 (males).
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Figure 5.39: Prevalence of BMI level 1 in
1981 (males).
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Figure 5.40: Prevalence of BMI level 2 in
1981 (males).
Age group
Pr
ev
a
le
nc
e 
R
at
e
1 2 3 4
0.
0
0.
1
0.
2
0.
3
Model before adj
Model after adj
Actual
Figure 5.41: Prevalence of BMI level 3 in
1981 (males).
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Figure 5.42: Prevalence of BMI level 4 in 1981 (males).
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Figure 5.43: Prevalence of BMI level 0 in
1981 (females).
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Figure 5.44: Prevalence of BMI level 1 in
1981 (females).
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Figure 5.45: Prevalence of BMI level 2 in
1981 (females).
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Figure 5.46: Prevalence of BMI level 3 in
1981 (females).
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Transition Variables
Changes
From To
BMI01
intercept −1.3093 −1.7093
age 0.011948 −0.711948
delete age2
BMI12
intercept −1.9734 −1.9034
intercept female age 0.02196 2.56426
intercept female age2 0.000025 −1.04805
BMI34 intercept female −1.7403 −4.891
BMI32 intercept −1.5636 −3.0636
BMI21 intercept female 0.2752 −1.0535
BMI10 intercept −5.1065 −6.5065
Table 5.12: Adjustments in BMI intensities for females.
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Figure 5.47: Prevalence of BMI level 4 in 1981 (females).
males are shown in Table 5.13. Figure 5.48 shows the estimated diabetes rates that
match the observed prevalence rates in 1981.
The adjustments for females are shown in Table 5.14. The adjustments are made
only to the forward transition from level 0 to 1. The estimated prevalence rates are
shown in Figure 5.49 together with the 1981 observed prevalence rates for diabetes.
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Figure 5.48: Prevalence of diabetes in 1981 (males).
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Figure 5.49: Prevalence of diabetes in 1981 (females).
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Transition Variables
Changes
From To
DIAB01
intercept −13.1194 −6.8894
age 0.2171 0.3971
age2 −0.00143 −2.80423
DIAB10
age 0.08451 4.19902
age2 −0.0007309 −1.1043
Table 5.13: Adjustments in diabetes intensities for males.
Transition Variables
Changes
From To
DIAB01
intercept −13.1194 −6.8394
age 0.2171 2.2971
Table 5.14: Adjustments in diabetes intensities for females.
5.4.4 Hypertension
For hypertension, we calculate the observed prevalence rates in 1981, which are shown
in Figures 3.38, 3.41, 3.44 and 3.47 for males and 3.50, 3.53, 3.56 and 3.59 for females
by using extrapolation between HALS84 and HALS91. The adjustments to the inten-
sities to match the 1981 observed prevalence rates are shown in Table 5.15 for males.
The HW model estimated prevalence rates after adjustments are shown in Figures
5.50 to 5.53.
The adjustments for hypertension for females are shown in Table 5.16. The HW
model estimated prevalence rates are shown in Figures 5.54 to 5.57.
Age group
Pr
ev
a
le
nc
e 
R
at
e
1 2 3 4
0.
0
0.
1
0.
2
Model before adj
Model after adj
Actual
Figure 5.50: Prevalence of h’ten level 0 in
1981 (males).
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Figure 5.51: Prevalence of h’ten level 1 in
1981 (males).
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Figure 5.52: Prevalence of h’ten level 2 in
1981 (males).
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Figure 5.53: Prevalence of h’ten level 3 in
1981 (males).
Transition Variables
Changes
From To
HTEN01
intercept −5.225 −1.7735
delete age
age2 −0.0005662 −0.5441
HTEN12
intercept −5.4559 −3.01365
age 0.1102 2.05219
age2 −0.0008271 −2.4948
HTEN23
intercept 6.107 −1.6595
age 0.09257 0.22323
age2 −0.0006924 −1.06539
HTEN32
intercept −1.4509 −1.9994
age −0.00757 −0.00467
delete age2
HTEN21
intercept −1.5793 −2.5233
age −0.01088 −0.03728
delete age2
HTEN10
intercept −2.0782 −3.031025
age −0.009779 −0.00054
delete age2
Table 5.15: Adjustments in h’ten intensities for males.
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Transition Variables
Changes
From To
HTEN01
intercept female 0.6956 1.7585
age female −0.07454 1.02225
age2 female 0.0006254 1.03688
HTEN12
intercept female 1.8886 −1.32445
age female −0.06396 0.223542
age2 female −0.0007594 −0.8650998
HTEN23
age female −0.06978 3.45167
age2 female −0.001118 −2.13997
HTEN21 intercept 1.3806 −0.660175
HTEN10
intercept female 2.4998 1.41625
age female −0.0000129 −2.007218
age2 female −0.0.0000129 1.13997
Table 5.16: Adjustments in h’ten intensities for females.
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Figure 5.54: Prevalence of h’ten level 0 in
1981 (females).
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Figure 5.55: Prevalence of h’ten level 1 in
1981 (females).
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Figure 5.56: Prevalence of h’ten level 2 in
1981 (females).
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Figure 5.57: Prevalence of h’ten level 3 in
1981 (females).
5.4.5 Hypercholesterolaemia
We make adjustments to the transition intensities to match the hypercholesterolaemia
observed prevalence rates in 1981. The 1981 observed prevalence rates are calculated
from HSE 1994 and 2003 and are explained in Chapter 3. The adjustments are shown
in Table 5.17 for males. The estimated prevalence rates from the adjusted model with
the observed prevalence rates are shown in Figures 5.58 to 5.61 for males. We used
the 2000 adjusted intensities as the starting intensities to adjust the model to match
the 1981 observed prevalence rates for females. The HW model estimated prevalence
rates are shown in Table 5.18. Figures 5.62 to 5.65 show the adjusted rates estimated
from the HW model for females.
5.4.6 IHD, stroke and IHD and/or stroke
For IHD and stroke, we only have data from HSE. So we used the observed prevalence
rates from 1994 and 2006 to extrapolate the 1981 observed prevalence rates. The
adjustments to the transition intensities for males are shown in Table 5.19. The
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Transition Variables
Changes
From To
HCHOL01
intercept −0.8141 −1.0141
age 0.0005 2.51305
age2 −0.0000000001 6.00496
HCHOL12
intercept −0.5372 −3.7172
delete age
age2 −0.001079 −15.436
HCHOL23
intercept −0.0056 −2.3056
age −0.035 0.0305
delete age2
HCHOL32
age 0.04828 0.14828
age2 −0.0004436 1.436
HCHOL21
intercept −4.0572 −3.4972
delete age
delete age2
HCHOL10
intercept −1.1261 −3.6261
delete age
delete age2
Table 5.17: Adjustments in h’chol intensities for males.
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Figure 5.58: Prevalence of h’chol level 0
in 1981 (males).
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Figure 5.59: Prevalence of h’chol level 1
in 1981 (males).
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Figure 5.60: Prevalence of h’chol level 2
in 1981 (males).
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Figure 5.61: Prevalence of h’chol level 3
in 1981 (males).
Transition Variables
Changes
From To
HCHOL01
intercept female 3.3207 −0.85295
age female −0.1528 4.91305
age2 female 0.001638 −3.0549605
HCHOL12
intercept female 2.6730 −0.80395
age female −0.08472 0.00559
age2 female 0.0011035 −0.58621
HCHOL23
intercept female −9.8716 −1.3205
age female −0.01509 2.08671
age2 female 0.00075 −1.08621
HCHOL32 intercept female −0.0158 −2.1912
HCHOL21
age female −0.08474 1.35057
delete age2 female
HCHOL10
age female −0.1765 −1.21718
age2 female 0.0013596 3.595139
Table 5.18: Adjustments in h’chol intensities for females.
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Figure 5.62: Prevalence of h’chol level 0
in 1981 (females).
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Figure 5.63: Prevalence of h’chol level 1
in 1981 (females).
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Figure 5.64: Prevalence of h’chol level 2
in 1981 (females).
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Figure 5.65: Prevalence of h’chol level 3
in 1981 (females).
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estimated prevalence rates from the adjusted model are shown in Figures 5.66, 5.67
and 5.68 for males.
Table 5.20 shows the adjustments that have been made to the IHD and stroke
intensities to match the HW model estimated prevalence rates with 1981 observed
prevalence rates for females. Figures 5.69, 5.70 and 5.71 show the estimated and
observed prevalence rates for females.
Transition Variables
Changes
From To
MI
intercept −10.8973 −8.0138
age 0.06967 8.46977
add age2 −9.164172
AP
intercept −15.83 −6.645
age 0.3003 2.0281
age2 0.002252 −3.164172
Stroke
intercept −11.8289 −9.0694
age 0.08779 12.72149
add age2 −14.764172
TIA
age 0.3201 5.9283
age2 −0.001708 −17.641388
Table 5.19: Adjustments in IHD and stroke intensities for males.
5.4.7 Mortality
For mortality of males, we use ELT14 as the 1981 observed mortality rates. Only one
adjustment was needed to increase the model estimated rates at higher ages. The
adjustment is made to the age coefficient, from 1.85535 to 2.25535. Figure 5.72 shows
the model estimated rates with the observed mortality rates in 1981.
For females, a similar adjustment to the age coefficient is made to the female
mortality intensities. The estimated mortality rates from the adjusted model and the
observed 1981 rates are shown in Figure 5.73.
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Figure 5.66: Prevalence of IHD in 1981
(males).
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Figure 5.67: Prevalence of stroke in 1981
(males).
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Figure 5.68: Prevalence of IHD and/or stroke in 1981 (males).
Transition Variables
Changes
From To
MI
intercept −10.8773 −7.0138
age 0.06967 8.46977
add age2 −8.654172
AP
intercept female −0.4767 −6.645
add age female 2.0281
add female age2 6.164172
CI
intercept female −0.7155 −15.46475
add age female 0.300663
Stroke intercept −11.8289 −8.7694
TIA age2 −0.001708 −3.641388
Table 5.20: Adjustments in IHD, stroke and IHD and/or stroke intensities for
females.
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Figure 5.69: Prevalence of IHD in 1981
(females).
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Figure 5.70: Prevalence of stroke in 1981
(females).
Age group
Pr
ev
a
le
nc
e 
R
at
e
50 60 70 80
0.
0
0.
1
0.
2
Model after adj
Actual
Figure 5.71: Prevalence of IHD and/or stroke in 1981 (females).
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Figure 5.72: Mortality rates in 1981 (males).
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Figure 5.73: Mortality rates in 1981 (females).
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5.5 Summary
Adjustments are based on the sequence of the significant risk factors as explained in
Section 5.1. A factor that has more influence on other risk factors requires more ad-
justments as we can see in BMI. From what we have done, BMI has more adjustments
than diabetes for males and females. For hypercholesterolaemia, as this risk factor is
not affected by changes in other risk factors, there were more adjustments for males
and females. The 1981 and 2000 adjusted models will be used to find the effect on
IHD, stroke and mortality if the risk factor rates in 2000 were the same as in 1981.
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Chapter 6
Effect of Changes
6.1 Introduction
The IMPACT Model calculates the extent to which deaths have reduced between
1981 and 2000 due to changes in cardiovascular risk factors and medical and surgical
treatments. Unal et al. (2005) stated that there were 68,230 fewer IHD deaths in
2000, of which 58% (35,944) are the results of changes in cardiovascular risk factors.
The factor that contributes the most to the reduction is smoking. We will carry
out similar calculations using our adjusted HW Model. We find out which factors
contribute the most to the reduction and by how much. We are also interested to see
how these changes affect the number of IHD and stroke incidents in 2000.
For the HW Model, we now have two parameterisations, one that is consistent
with 1981 prevalences and one consistent with 2000 prevalences. For the HW model
with the 1981 parameterisation, we use the 1960 observed prevalence rates as the
initial risk profiles and for the HW model with the 2000 parameterisation, we use the
1981 observed prevalence rates as the initial risk profiles. We are interested to see
what would have happened if the intensities in 1981 for the risk factors remained the
same in 2000. The effect of changes will be explored by changing the factors one at
a time and also by combining such changes one by one. The sequence of risk factors
that we will use to calculate the effect will follow the order suggested by Figure 5.1,
i.e. we will apply the IHD, stroke and mortality rates to the England and Wales
population in 2000 and see how the risk factor changes affect these rates. We focus
on ages from 45 to 84 and divide these ages into four age groups. Table 6.1 shows
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the age structure of the 2000 (ONS, 2004) population of England and Wales in each
age group for males and females. The percentage of change is calculated using the
formula
((Fixed factor results− 2000 results) /2000 results)× 100 (6.1)
where the fixed factor result is the total expected number of deaths for the total
population of England and Wales in 2000 from ages 45 to 84 from the model estimated
prevalence rates calculated using the HW Model for which either one factor or a
combination of factors has been kept fixed to 1981 intensities and the changes are
over all age groups with other factors using 2000 intensities. 2000 results are total
expected number of deaths for total population of England and Wales in 2000 from
ages 45 to 84 from the model estimated prevalence rates calculated using the HW
Model with intensities consistent with 2000 observed prevalence rates which will be
identified as the 2000 HW model. The difference is divided by the 2000 results as we
would like to see what would have happened to the 2000 model estimated prevalence
rates if one or more risk factors had been the same as in 1981. For the fixed factor
results and the 2000 results, we will use the Heriot-Watt model with the 1981 risk
profiles as the initial risk profiles.
Age group Male Female
45-54 3,412,800 3,468,000
55-64 2,687,900 2,758,900
65-74 2,040,200 2,332,100
75-84 1,148,500 1,758,300
Table 6.1: Population of England and Wales by age group in 2000.
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6.2 Single factor effects
6.2.1 Smoking
We start to investigate the effect of changes to the numbers of IHD, stroke and mor-
tality cases by using the smoking factor. Using the 2000 HW model with intensities
that match the 2000 observed prevalence rates and 1981 observed prevalence rates
as the initial risk profiles, we calculate the changes by replacing the 2000 smoking
rates with 1981 smoking rates. Table 6.2 shows the differences and the percentage of
changes between the HW model with the 1981 smoking rates with other intensities
consistent with 2000 observed prevalence rates and the HW model with everything
consistent with 2000 observed prevalence rates. Both are using the same initial risk
profiles which are the 1981 observed prevalence rates. As an example, the difference in
mortality for males is 20,462, as shown in Table 6.2. This means that there is a higher
number of deaths when we use the 1981 smoking rates compared to using the 2000
smoking rates in the HW model with other risk factors retaining the 2000 intensities
and using 1981 observed prevalence rates as the initial risk profiles. This represents
a 11.85% change when compared with the 2000 HW model. In other words, we can
say that if the 1981 smoking rates for males continued to persist in 2000, there would
have been a higher number of deaths by 11.85%.
Males
With the HWModel, we used the 2000 intensities with 1981 smoking rates to calculate
what would have happened if smoking rates had not changed since 1981. We start by
changing the 2000 smoking rates in the 2000 HW Model to the 1981 smoking rates.
The model estimated prevalence rates when we fixed one or more factor with the
1981 intensities are shown in blue, in Figure 6.1 for 1981 smoking rates, whereas the
model estimated prevalence rates from all factors consistent with 2000 intensities are
shown in red. The observed smoking rates are shown in Tables 3.2, 3.3 and 3.4. With
other risk factors intensities consistent with 2000 observed prevalence rates, the 1981
smoking prevalences will increase the mortality rates for our age groups by up to 12.5%
for males as seen in Figure 6.1 where the highest change is from 0.02452 to 0.02759
for age group 65-74. Table 6.2 shows the changes in the number of IHD cases, stroke
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and death in percentages. Smoking rates were higher in 1981 and this has increased
the number of stroke incidents and deaths by 8.70% and 11.85%, respectively. Higher
mortality rates for smokers with IHD has caused the number of IHD cases to reduce
by 0.88%.
Females
For females, similar changes as for males happen to stroke and mortality where the
model estimated prevalence rates increase by 2.75% and 6.46%, respectively, as there
are higher smoking rates in 1981. The IHD rates are higher when we fix smoking to
1981 smoking rates. Although smoking rates were higher in 1981, the IHD rates are
higher than the IHD rates from the 2000 HW model as the IHD rates are higher in
1981 than in 2000 as shown in Figures 3.88 and 6.2. The IHD rates are higher by
3.41% compared to the 2000 model with 2000 smoking rates as the mortality rates
are lower for females. This is different from males where IHD rates have reduced due
to higher mortality rates compared to females. The changes for females are shown in
Table 6.2.
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Figure 6.1: Mortality rates in 2000
(males): model (red) and with 1981
smoking rates (blue).
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Figure 6.2: IHD rates in 2000 (females):
model (red) and with 1981 smoking rates
(blue).
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Cases Male Female
Difference % changes Difference % changes
IHD −8962 −0.88 23770 3.41
Stroke 28196 8.70 9533 2.75
Mortality 20462 11.85 10277 6.46
Table 6.2: Changes when using 1981 smoking rates for total population in 2000 for
males and females.
6.2.2 BMI
Males
The definition of each BMI level is shown in Table 2.2. To see what would have
happened if BMI rates followed the same level as in 1981, we ran the 2000 Model for
19 years with 1981 BMI intensities. The results for males show that this will reduce
the rates of diabetes as there are lower rates of obesity. These can be seen in Figures
6.3 and 6.4. The prevalence rate for obesity has the highest effect on age group 75-84
where it is 86% lower if the 1981 levels continue to 2000 as we can see in Figure 6.3.
It also reduces diabetes rates by up to 14%, as we can see in Figure 6.4 where the
highest changes happen in age group 65-74.
Lower levels of BMI will tend to reduce the prevalence of diabetes and lower the
levels of hypertension (Chatterjee et. al, 2008(a), Tables 5 and 7). These, in turn, will
tend to reduce the prevalence of IHD and stroke (Chatterjee et. al, 2008(a), Table
9) which will then tend to reduce mortality. However, BMI has a direct U-shaped
effect on mortality (Chatterjee et. al, 2008(a), Table 11) so that the overall effect
of lower levels of BMI is an increase in the number of deaths. A slight decrease in
hypertension has reduced the IHD and stroke rates by 0.73% and 2.16%, respectively
as shown in Table 6.3. In the HW Model, an increase in hypertension levels 1, 2 and
3 will increase the IHD and stroke rates by a different factor. Hypertension level 3
has the highest factor that will increase the IHD and stroke rates, so reduction in
hypertension will slightly reduce these rates. Mortality rates are slightly higher than
the adjusted model when we fix BMI as we can see in Figure 6.5. Higher prevalence
of lightweight has increased the mortality rates by up to 8%. We can see that the
BMI level 0 and 1 are decreasing over time in Figures 3.2 and 3.5. In our model, a
lower level of BMI reduces the mortality rates by a factor lower than a higher level
of BMI. This means that a lower BMI level has higher mortality rates than a higher
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BMI level. The number of deaths would increase by 7.17% in 2000 if BMI had not
changed from 1981. Table 6.3 shows the percentage of changes for IHD, stroke and
mortality when 1981 BMI rates are considered.
Females
A similar trend in the percentage of changes for IHD, stroke and mortality occurs
for females when 1981 BMI intensities are considered in the 2000 Heriot-Watt model.
These changes are shown in Table 6.3. Lower obesity rates in 1981 have reduced the
IHD and stroke rates by 1.16% and 1.56%, respectively. We can see in Figures 3.23
and 3.26 that the observed prevalence rates for BMI levels 2 and 3 are increasing over
time. Higher lightweight rates for BMI has increased the number of deaths for females
by 1.51%. This is illustrated in Figure 6.6, although the differences are too small to
be seen clearly.
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Figure 6.3: Prevalence of obesity in 2000
(males): model (red) and with 1981 BMI
rates (blue).
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Figure 6.4: Prevalence of diabetes in 2000
(males): model (red) and with 1981 BMI
rates (blue).
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Figure 6.5: Mortality rates in 2000 (males): model (red) and with 1981 BMI rates
(blue).
Cases Male Female
Difference % changes Difference % changes
IHD −7448 −0.73 −8067 −1.16
Stroke −7001 −2.16 −5400 −1.56
Mortality 12374 7.17 2397 1.51
Table 6.3: Changes when using 1981 BMI for total population in 2000 for males and
females.
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Figure 6.6: Mortality rates in 2000 (females): model (red) and with 1981 BMI rates
(blue).
6.2.3 Diabetes
Males
We ran the HWModel with 1981 diabetes intensities to see what would have happened
if diabetes rates followed the same intensities as in 1981. The prevalence of diabetes127
Cases Male Female
Difference % changes Difference % changes
IHD −232 −0.02 −4911 −0.71
Stroke 1205 0.37 598 0.17
Mortality −3677 −2.13 −2408 −1.51
Table 6.4: Changes when using 1981 diabetes for total population in 2000 for males
and females.
with 1981 diabetes intensities is lower than the 2000 model estimated prevalence rates
as shown in Figure 6.7. This then reduces the number of deaths by 2.13% as shown
in Table 6.4 and the mortality rates are shown in Figure 6.8. The effect is different
than in the previous section, as here the BMI model estimated prevalence rates are
based on the oserved prevalence rates in 2000 which have a lower lightweight level
as explained in Section 6.2.2 and lower diabetes rates would reduce the mortality
rates. 1981 diabetes intensities have a small effect on hypertension, IHD and stroke.
It reduces the number of IHD cases by 0.02%. There is a small increase in stroke as
higher levels of obesity increase the hypertension rates slightly. Diabetes has a direct
effect on IHD and mortality, but not on stroke (Chatterjee et. al, 2008(a), Tables
9 & 11). Hence, lower prevalence of diabetes will tend to reduce the prevalence of
IHD and reduce the number of deaths. A reduced number of deaths will increase the
prevalence of stroke. These can be seen in Table 6.4.
Females
Table 6.4 shows the percentage of changes for IHD, stroke and mortality for females
when we considered 1981 diabetes intensities in the 2000 HW model. The changes are
similar to the males. The diabetes rates are lower in 1981 as we can see in Figure 3.35
and these have reduced the IHD and mortality rates by 0.71% and 1.51%, respectively.
The mortality rates are also lower than the 2000 HW model as we are using the 2000
BMI intensities that have lower lightweight rates as mentioned for males. The stroke
rates have increased slightly by 0.17% as the hypertension rates are slightly higher
due to higher rates of obesity.
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Figure 6.7: Prevalence of diabetes in 2000
(males): model (red) and with 1981
diabetes rates (blue).
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Figure 6.8: Mortality rates in 2000
(males): model (red) and with 1981
diabetes rates (blue).
6.2.4 Hypertension
Males
After diabetes, we then use the 2000 HW model with 1981 hypertension intensities.
The hypertension rates in 2000, if there are no changes in hypertension since 1981,
are generally higher than the model estimated prevalence rates. This is shown in
Figure 6.9 where the model estimated prevalence rates increase by up to 19% for
age groups 45-54, 55-64 and 65-74 but there is a slight decrease for age group 75-84.
Hypertension is defined as a combination of levels 2 and 3 where the definition of
each level is shown in Table 3.5. Hypertension has a direct effect on IHD, stroke
and mortality (Chatterjee et. al, 2008(a), Tables 9 & 11). Increasing the levels of
hypertension to 1981 levels will tend to increase the prevalence of IHD and stroke
and the number of deaths. This can be seen in Figures 6.10, 6.11 and 6.12 where
the model estimated prevalence rates with the adjusted intensities are higher than
the model estimated prevalence rates from the 2000 HW model. Table 6.5 shows a
higher percentage of changes in IHD and stroke compared to previous risk factors.
1981 hypertension intensities have increased the numbers of IHD and stroke cases by
6.06% and 12.98%, respectively. It also increases the number of deaths by 7.26%. We
can see in Figures 3.47 for males and 3.59 for females that the hypertension level 3
rates are higher in 1981 than in 2000.
129
Cases Male Female
Difference % changes Difference % changes
IHD 61712 6.06 34899 5.01
Stroke 42082 12.98 46044 13.28
Mortality 12530 7.26 9497 5.97
Table 6.5: Changes when using 1981 h’ten for total population in 2000 for males and
females.
Females
Similar changes can be seen for females in Table 6.5. The number of IHD and stroke
cases increases by 5.01% and 13.28%, respectively, when the hypertension intensities
in 2000 are similar to the 1981 intensities. The number of deaths has also increased
by 5.97%.
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Figure 6.9: Prevalence of h’ten in 2000
(males): model (red) and with 1981 h’ten
rates (blue).
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Figure 6.10: Prevalence of IHD in 2000
(males): model (red) and with 1981 h’ten
rates (blue).
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Figure 6.11: Prevalence of stroke in 2000
(males): model (red) and with 1981 h’ten
rates (blue).
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Figure 6.12: Mortality rates in 2000
(males): model (red) and with 1981 h’ten
rates (blue).
6.2.5 Hypercholesterolaemia
Males
The next factor to be fixed in the 2000 HW Model is hypercholesterolaemia. The
model estimated prevalence rates, if we use the 1981 hypercholesterolaemia intensi-
ties, are higher than the model estimated prevalence rates from the 2000 HW model.
This is shown in Figure 6.13 which refers to a combination of hypercholesterolaemia
levels 1, 2 and 3. The definition of each level is shown in Table 3.6. Hypercholestero-
laemia has a direct effect on IHD but not on stroke (Chatterjee et. al, 2008(a), Table
9). It has a mixed effect on mortality (Chatterjee et. al, 2008(a), Table 11). The
hypercholesterolaemia rates increase by up to 19% especially in age group 64-74 as
shown in Figure 6.13. IHD and stroke rates have increased slightly when we use the
1981 hypercholesterolaemia intensities. Table 6.6 shows there is a small effect on IHD,
stroke and mortality where the percentages of changes are between -0.80% to 0.28%.
A higher level of hypercholesterolaemia (levels 1, 2 and 3) has slightly increased the
IHD and stroke rates but reduced the mortality rates. This is because when hyperc-
holesterolaemia is fixed to 1981 observed prevalence rates, the hypercholesterolaemia
rates in levels 1 and 3 are higher than the 2000 model estimated prevalence rates
which will reduce the mortality rates.
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Females
For females, only IHD has the same positive change as males where it increases the
number of IHD cases by 2.63% as the hypercholesterolaemia rates are higher in 1981
than 2000. Higher 1981 hypercholesterolaemia rates have also increased the number
of deaths by 1.18%. Increasing hypercholesterolaemia to 1981 levels increases the
prevalence of IHD, particularly for females, but has little effect on the prevalence
of stroke or the numbers of deaths. There is a slight reduction in the number of
stroke cases when we fixed hypercholesterolaemia as for females, although there is a
decreasing trend over time, the 1981 hypercholesterolaemia rates for age group 80 are
lower than the 2000 model estimated prevalence rates as we can see in Figure 6.14.
The percentage changes for females are shown in Table 6.6.
Cases Male Female
Difference % changes Difference % changes
IHD 1340 0.13 18302 2.63
Stroke 905 0.28 −863 −0.25
Mortality −1388 −0.80 1877 1.18
Table 6.6: Changes when using 1981 h’chol for total population in 2000 for males
and females.
6.2.6 IHD
Males
We then calculate the effect of changes in IHD and include the adjustments for sudden
deaths in 1981. In Figures 6.15 and 6.16, the model estimated prevalence rates for IHD
and stroke with IHD intensities being consistent with 1981 intensities are lower than
the 2000 model estimated prevalence rates. This has decreased the number of IHD
cases by 29.33%, as shown in Table 6.7 and has reduced stroke cases by 4.29%. When
we fix IHD, the number of deaths increases by 8.99% and we can see in Figure 6.17
that the model estimated prevalence rates with fixed IHD intensities are higher than
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Figure 6.13: Prevalence of h’chol in 2000
(males): model (red) and with 1981 h’chol
rates (blue).
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Figure 6.14: Prevalence of h’chol in 2000
(females): model (red) and with 1981
h’chol rates (blue).
the 2000 model estimated prevalence rates. The mortality rates are higher although
the IHD and stroke rates have decreased. This is due to the rates of sudden deaths
from IHD are much higher in 1981. The difference in mortality for males are higher
than for females, as shown in Table 6.7. For sudden deaths following a myocardial
infarction model, sex is not an explanatory variable as explained in Section 4.2.1.
The IHD observed rates are lower in 1981 than in 2000 for males but the observed
prevalence rates are slightly higher than females over time, shown in Figures 3.85 and
3.88. This could explained why the difference for the number of deaths are higher for
males.
Females
If we change the 2000 IHD intensities with the 1981 IHD intensities and also include
the changes for sudden deaths in 1981, the number of IHD cases for females are higher
than in the 2000 HW model. This is because there is a decreasing trend over time for
IHD rates for females as shown in Figure 3.88 especially at younger age groups. So
higher IHD rates in 1981 have increased the number of IHD cases by 2.74% especially
for age groups 60 and 70. The number of stroke cases and number of deaths have
similar changes as for males. As shown in Table 6.7, the number of stroke cases
reduced by 1.64%. This slight decrease in stroke rates is due to a slight decrease
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in IHD rates for age groups 50 and 80. The number of deaths increased by 0.86%
because of higher IHD rates in 1981 which will increase the number of sudden deaths
following a myocardial infarction.
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Figure 6.15: Prevalence of IHD in 2000 (males): model (red) and with 1981 IHD
rates (blue).
Cases Male Female
Difference % changes Difference % changes
IHD −298616 −29.33 19102 2.74
Stroke −13919 −4.29 −5687 −1.64
Mortality 15532 8.99 1374 0.86
Table 6.7: Changes when using 1981 IHD for total population in 2000.
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Figure 6.16: Prevalence of stroke in 2000
(males): model (red) and with 1981 IHD
rates (blue).
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Figure 6.17: Mortality rates in 2000
(males): model (red) and with 1981 IHD
rates (blue).
6.2.7 Stroke
Males
After IHD, we calculate the effect of changes in stroke. If stroke intensities are the
same as in 1981, the model estimated prevalence rates with fixed 1981 stroke intensities
for stroke are lower than the 2000 model estimated prevalence rates as shown in Figure
6.18. With other factors being equal to the observed prevalence rates in 2000, the
intensities of stroke in 1981 have reduced stroke cases by 54.53% and this will affect
mortality by reducing it by 10.11%, as shown in Table 6.8 and Figure 6.19. The
increasing trend over time in IHD rates has caused the IHD cases to increase by
2.54%. When we fixed the stroke intensities to 1981 intensities, the IHD and other
risk factors intensities are the 2000 intensities with higher model estimated prevalence
rates for diabetes, hypertension level 3 and hypercholesterolaemia level 3.
Females
The changes for females are also similar to males for IHD, stroke and mortality. The
number of IHD cases has increased by 1.03% if the 1981 stroke rates remain in 2000
which is similar to males. The number of stroke cases and the number of deaths
will reduce by 60.47% and 6.61%, respectively when stroke is fixed to 1981 observed
prevalence rates. These changes are shown in Table 6.8.
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Figure 6.18: Prevalence of stroke in 2000
(males): model (red) and with 1981 stroke
rates (blue).
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Figure 6.19: Mortality rates in 2000
(males): model (red) and with 1981 stroke
rates (blue).
Cases Male Female
Difference % changes Difference % changes
IHD 25864 2.54 7180 1.03
Stroke −176749 −54.53 −209602 −60.47
Mortality −17458 −10.11 −10516 −6.61
Table 6.8: Changes when using 1981 stroke for total population in 2000 for males
and females.
6.2.8 Mortality
Males
The final factor that we consider here is mortality. Using the 1981 mortality intensities
has caused mortality to be higher than the estimated rates from the 2000 HW model
especially at older ages. This is shown in Figure 6.21. The number of deaths will
increase by 28.16% if the mortality intensities in 1981 continue to 2000. There are
slight reductions in the prevalence of obesity, diabetes and hypertension and these
have caused the number of IHD and stroke cases to reduce by 0.49% and 5.01%,
respectively. The model estimated rates for stroke are shown in Figure 6.20 where
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the differences are mostly at older ages.
Females
Table 6.9 shows the percentage of changes for IHD, stroke and mortality for females.
When we fixed mortality with the 1981 intensities, the number of deaths increased by
30.81%. With other risk factors consistent with the 2000 intensities, the numbers of
IHD and stroke cases have reduced by 2.71% and 2.46%, respectively.
Cases Male Female
Difference % changes Difference % changes
IHD −4968 −0.49 −18841 −2.71
Stroke −16228 −5.01 −8522 −2.46
Mortality 48632 28.16 48998 30.81
Table 6.9: Changes when using 1981 mortality for total population in 2000 for males
and females.
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Figure 6.20: Prevalence of stroke in 2000
(males): model (red) and with 1981
mortality rates (blue).
50 55 60 65 70 75 80
0.
00
0.
05
0.
10
0.
15
0.
20
Age group
Pr
ev
a
le
nc
e 
R
at
e
2000
Fixed 1981
Figure 6.21: Mortality rates in 2000
(males): model (red) and with 1981
mortality rates (blue).
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6.2.9 Conclusions
From the results in these sections, we see that hypertension has a higher effect on
IHD and stroke for males, where if the intensities are similar to 1981, there will be
higher prevalence of IHD and stroke by 6.06% and 12.98%, respectively. This is also
the same for females; hypertension has the highest effect on IHD and stroke and the
number of IHD cases increased by 5.01% and the number of stroke cases increased by
13.28%. If IHD rates in 2000 had the same level as in 1981, there would be 29.33%
less cases of IHD in males. There is a similar effect with stroke where the number
of strokes would be reduced by 54.5%. For females, there is a positive change for
IHD as IHD rates in 1981 are higher than in 2000. The number of stroke cases for
females reduces by 60.47% if stroke intensities in 2000 have similar intensities as in
1981. Higher observed prevalence rates for sudden deaths following MI in 1981 have
increase the mortality for males and females when IHD is fix. Beside mortality itself,
smoking has the highest effect on mortality for males where deaths have reduced by
20462 with the reduction in smoking rates between 1981 and 2000. This is consistent
with the IMPACT Model where smoking is the biggest contributor in reducing the
number of IHD deaths by 29,715. For females, changes in smoking between 1981
and 2000 will reduce the number of deaths by 10,277. The risk factor with the least
influence on mortality rates for males and females is hypercholesterolaemia.
6.3 Effects of combinations of factors
In this section, we will combine the risk factors one by one to see how these combina-
tions of 1981 risk factors intensities affect the number of IHD cases, stroke cases and
mortality in 2000. We add risk factors to the considered combinations based on the
order of influence suggested in Figure 5.1. We started with BMI in Section 6.2.2 and
we will add diabetes in the following section.
6.3.1 BMI and diabetes
Males
We first fix the BMI and diabetes 1981 intensities and run the model with 2000
intensities for the other factors. With 1981 BMI and diabetes intensities, there will
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be lower obesity and diabetes rates. These are not surprising as we would expect the
model estimated prevalence rates to be similar to the model estimated prevalence rates
shown in Figures 6.3 and 6.7. Mortality rates are higher than model estimated rates
in 2000, when we use 1981 BMI and diabetes intensities as shown in Figure 6.22.
Higher prevalence of lightweight has increased the mortality rates but the increase
in mortality rates is lower than when we use the model with 1981 BMI intensities
only which is shown in Table 6.3 in Section 6.2.2. The combination of 1981 BMI
intensities with the 1981 diabetes intensities has reduced the increment of mortality
rates as diabetes rates are lower than actual in 2000. The numbers of IHD and stroke
cases have reduced slightly due to the decrease in BMI, diabetes and hypertension by
0.75% and 1.81% respectively, but the number of deaths increased by 5.18% as shown
in Table 6.10.
Females
This is also similar to males where the number of IHD and stroke cases decreased by
1.82% and 1.40%, respectively for the same reason as males. The number of deaths
increased slightly by 0.09%. The percentage changes are shown in Table 6.10.
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Figure 6.22: Mortality rates in 2000 (males): model (red) and with 1981 BMI and
diabetes rates (blue).
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Cases Male Female
Difference % changes Difference % changes
IHD −7649 −0.75 −12642 −1.82
Stroke −5882 −1.81 −4836 −1.40
Mortality 8937 5.18 143 0.09
Table 6.10: Changes when using 1981 BMI and diabetes for total population in 2000
(males).
Cases Male Female
Difference % changes Difference % changes
IHD 56122 5.51 24688 3.55
Stroke 35633 10.99 42800 12.35
Mortality 22007 12.74 9958 6.26
Table 6.11: Changes when using 1981 BMI, diabetes and h’ten for total population
in 2000 for males and females.
6.3.2 BMI, diabetes and hypertension
Males
The next factor that we add to the previous combination is hypertension. When
BMI, diabetes and hypertension intensities are consistent with 1981, there will be
lower obesity and diabetes rates and a slight increase in the hypertension rates. The
increase in hypertension has a big effect on IHD, stroke and mortality; it increases
IHD by 5.51% and stroke by 10.99%. These can be seen in Figures 6.23, 6.24 and
6.25. The number of deaths has also increased by 12.74%. These figures are shown
in Table 6.11 and the mortality rates are shown in Figure 6.26.
Females
The trend over time for BMI, diabetes and hypertension for females is similar to males
so the percentage of changes for IHD, stroke and mortality are all positive, as shown
in Table 6.11. When we fixed BMI, diabetes and hypertension with 1981 observed
prevalence rates, the number of IHD cases, number of stroke cases and number of
deaths increase by 3.55%, 12.35% and 6.26%, respectively.
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Figure 6.23: Prevalence of h’ten in 2000
(males): model (red) and with 1981 BMI,
diabetes and h’ten rates (blue).
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Figure 6.24: Prevalence of IHD in 2000
(males): model (red) and with 1981 BMI,
diabetes and h’ten rates (blue).
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Figure 6.25: Prevalence of stroke in 2000
(males): model (red) and with 1981 BMI,
diabetes and h’ten rates (blue).
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Figure 6.26: Mortality rates in 2000
(males): model (red) and with 1981 BMI,
diabetes and h’ten rates (blue).
6.3.3 BMI, diabetes, hypertension and hypercholesterolaemia
Males
We then combine the previous factors with hypercholesterolaemia. With a combina-
tion of 1981 hypercholesterolaemia intensities, the IHD and stroke rates are slightly
higher than for the previous combination, as shown in Figures 6.27 and 6.28, while
mortality rates, shown in Figure 6.29, have also increased, though the increase,
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11.84%, is less than for BMI, diabetes and hypertension (12.74%). This is consis-
tent with what is shown in Section 6.2.5 where 1981 hypercholesterolaemia intensities
have reduced the mortality rates slightly due to increases in hypercholesterolaemia
levels 1 and 3 in 2000. The percentage of changes can be seen in Table 6.12.
Females
Table 6.12 also shows the percentage of changes for IHD, stroke and mortality for fe-
males. For females, adding hypercholesterolaemia has increased the number of deaths
from 6.26% to 7.05% from the previous combination due to the increase in IHD rates.
This combination has increased the number of IHD cases by 6.23% and reduced the
number stroke cases by 12.05%.
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Figure 6.27: Prevalence of IHD in 2000 (males): model (red) and with 1981 BMI,
diabetes, h’ten and h’chol rates (blue).
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Figure 6.28: Prevalence of stroke in 2000
(males): model (red) and with 1981 BMI,
diabetes, h’ten and h’chol rates (blue).
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Figure 6.29: Mortality rates in 2000
(males): model (red) and with 1981 BMI,
diabetes, h’ten and h’chol rates (blue).
Cases Male Female
Difference % changes Difference % changes
IHD 57367 5.63 43394 6.23
Stroke 36726 11.33 41777 12.05
Mortality 20440 11.84 11924 7.5
Table 6.12: Changes when using 1981 BMI, diabetes, h’ten and h’chol for total
population in 2000 for males and females.
6.3.4 BMI, diabetes, hypertension, hypercholesterolaemia and
IHD
Males
We then add IHD to the combination of BMI, diabetes, hypertension and hyperc-
holesterolaemia. This has caused the IHD rate to be lower than actual with an effect
similar to that shown in Figure 6.15; IHD cases reduced by 25.47%, which is shown
in Table 6.13. Adding IHD has also lowered the change in the number of stroke cases
as shown in Table 6.13 where the cases increase by 6.43%, as compared to 11.33% in
Table 6.12. It increased the number of deaths by an additional of 10.3% (from 11.84%
to 22.14%) compared to the previous combination. The prevelance of IHD is lower
but there is a large increase in mortality. This is due to the rates of sudden deaths
as explained in Section 6.2.6. The mortality rates are shown in Figure 6.30 where
the model estimated prevalence rates from this combination are higher than the 2000
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model estimated prevalence rates.
Females
For females, this combination has increased the number of IHD cases from 6.23% to
11.44%. This is due to the decreasing trend over time for IHD rates for females. The
1981 IHD rates are higher than 2000 model estimated prevalence rates for most age
groups. It has reduced the number of stroke cases from the previous combination to
9.88% and increased the number of deaths to 9.18%. These changes are shown in
Table 6.13.
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Figure 6.30: Mortality rates in 2000
(males): model (red) and with 1981 BMI,
diabetes, h’ten, h’chol and IHD rates
(blue).
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Figure 6.31: Mortality rates in 2000
(males): model (red) and with 1981 BMI,
diabetes, h’ten, h’chol, IHD and stroke
rates (blue).
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Cases Male Female
Difference % changes Difference % changes
IHD −259304 −25.47 79606 11.44
Stroke 20846 6.43 34255 9.88
Mortality 38232 22.14 14602 9.18
Table 6.13: Changes when using 1981 BMI, diabetes, h’ten, h’chol and IHD for total
population in 2000 for males and females.
6.3.5 BMI, diabetes, hypertension, hypercholesterolaemia, IHD
and stroke
Males
The next factor to be added is stroke. IHD and stroke rates in 1981 are lower compared
to 2000 model estimated prevalence rates, as seen in Figures 6.15 and 6.18, so there
are reductions in the numbers of IHD and stroke cases as shown in Table 6.14. Using
this combination, the number of stroke cases reduced by 52.81%. Because stroke cases
are reduced by more than 50%, the change in the number of deaths has reduced from
22.14% in the previous combination to 10.47%. We can see in Figure 6.31 that the
mortality rates for this combination are slightly lower than the 2000 model estimated
prevalence rates at age group 80 and this has also contributed to the reduction in
changes in the number of deaths.
Females
Adding stroke in the combination for females has increased the IHD rates slightly by
12.08%. It has reduced the number of stroke cases by 56.99% and reduced the number
of deaths to 1.10% from the previous combination. Table 6.14 shows the percentage
of changes for females.
Cases Male Female
Difference % changes Difference % changes
IHD −247802 −24.34 84082 12.08
Stroke −171155 −52.81 −197522 −56.99
Mortality 18087 10.47 1747 1.10
Table 6.14: Changes when using 1981 BMI, diabetes, h’ten, h’chol, IHD and stroke
for total population in 2000 for males and females.
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6.3.6 BMI, diabetes, hypertension, hypercholesterolaemia, IHD,
stroke and mortality
Males
The last factor to be included in the combination is mortality. Mortality rates in 1981
are higher than in 2000. This can be seen from Figure 6.32. Using this combination,
the whole set of intensities is consistent with the 1981 observed prevalence rates. IHD
and stroke rates are lower compared to 2000 model estimated prevalence rates, so
there are reductions in the number of IHD and stroke cases as shown in Table 6.15
and the changes are slightly higher than for the previous combination. The mortality
rates from this combination are close to the observed mortality rates in 1981. The
only difference from the 1981 observed mortality rates is that the smoking rates used
are the observed rates in 2000. If the same mortality level continued with all 1981
intensities for other factors, there would be 40.84% more deaths.
Females
Table 6.15 shows the percentage of changes for females when the whole set of in-
tensities is consistent with 1981 observed rates. The number of IHD cases increased
by 7.37% and the number of stroke cases further decreased by 58.01%. With 1981
mortality intensities added to the combination, the changes in the number of deaths
increased from 1.10% to 32.87%.
Cases Male Female
Difference % changes Difference % changes
IHD −279821 −27.48 51283 7.37
Stroke −181035 −55.85 −201069 −58.01
Mortality 70527 40.84 52271 32.87
Table 6.15: Changes when using 1981 BMI, diabetes, h’ten, h’chol, IHD, stroke and
mortality for total population in 2000 (males).
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Figure 6.32: Mortality rates in 2000 (males): model (red) and with 1981 BMI,
diabetes, h’ten, h’chol,IHD, stroke and mortality rates (blue).
6.3.7 Conclusions
When we add the risk factors sequentially, hypertension and hypercholesterolaemia
have increased the IHD and stroke rates for males, as these intensities are higher in
1981. Beside mortality itself, the highest increment happens when we add IHD where
the mortality rates increased by 10.3% from the previous combination and reduced
by 11.67% when stroke is added. Mortality in males would increase by 40.84% if the
intensities of all risk factors in 2000 were the same as in 1981 except for smoking.
For females, adding hypertension and hypercholesterolaemia to the combination
has a similar effect as for males where the IHD and stroke rates are higher than the
2000 observed prevalence rates. 1981 IHD intensities have increased the number of
IHD cases compared to the 2000 model estimated prevalence rates. This happens as
1981 IHD rates are higher than 2000 observed prevalence rates in most age groups
for females. Adding stroke to the combination for females has reduced the number of
deaths from 14602 to 1747 and having all risk factors’ levels fixed to 1981 observed
prevalence rates except for smoking would increase the number of deaths by 32.87%.
Tables 6.16 and 6.19 show the expected number of deaths for each age group as
the factors are held one by one at the 1981 levels for males and females, respectively.
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The labels in the Tables 6.16, 6.17, 6.18, 6.19, 6.20, 6.21 and Figures 6.33 to 6.36 are
explained below and labels with ∗ indicating that 1981 smoking rates are included in
the combination, and also "fixed" implies "fixed to 1981 intensities":
a: 2000 model estimated prevalence rates with smoking fixed
b: 2000 model estimated prevalence rates with BMI fixed
c: 2000 model estimated prevalence rates with BMI and diabetes fixed
d: 2000 model estimated prevalence rates with BMI, diabetes and hypertension fixed
e: 2000 model estimated prevalence rates with BMI, diabetes, hypertension and hy-
percholesterolaemia fixed
f: 2000 model estimated prevalence rates with BMI, diabetes, hypertension, hyperc-
holesterolaemia and IHD fixed
g: 2000 model estimated prevalence rates with BMI, diabetes, hypertension, hyperc-
holesterolaemia, IHD and stroke fixed
h: 2000 model estimated prevalence rates with BMI, diabetes, hypertension, hyperc-
holesterolaemia, IHD, stroke and mortality fixed
i: 2000 model estimated prevalence rates with smoking, BMI, diabetes, hypertension,
hypercholesterolaemia, IHD, stroke and mortality fixed
In Tables 6.16 to 6.21, the difference with the previous combination is calculated
by finding the difference between the total expected deaths in the combination with
the total deaths from the previous combination. For combination a, it is the difference
between the total expected deaths in combination a with the total expected deaths
using the 2000 model estimated prevalence rates.
From Table 6.16 for males, we can see that the expected number of deaths in 1981
is higher than in 2000. If smoking rates were the same as in 1981 (a), there would
be more deaths in all age groups and changes in smoking have the highest effect on
deaths among the risk factors. It is a similar story for females as shown in Table
6.19, where the number of deaths due to 1981 smoking rates has increased by 10277
(169302−159025). When we fixed BMI (b), it has given the most effect on the oldest
age group where there are 6000 (91514−85689) more deaths than the 2000 model
estimated prevalence rates for males. For females, the increment is not as high as for
males. Adding diabetes to the combination, we can see fewer deaths in all age groups
for males and females.
The combination of factors with hypertension further increases the number of
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deaths by 13069 and 9815 for males and females, respectively. Hypercholesterolaemia
has the least effect on mortality where by adding it to the combination, it reduces the
number of deaths for males by 1567. A different effect is observed for females where
the number of deaths increases by 1966 when hypercholesterolaemia is added to the
combination.
As for events, IHD has the highest effect on mortality where it increases deaths
for males by 38231 (210910−172679), compared to the 2000 model estimated preva-
lence rates. This is also similar to females, where it increases deaths by 14602
(173627−159025) compared to the 2000 model estimated prevalence rates. If all fac-
tors and events including mortality are not changed from 1981, there will be an addi-
tional 70527 (243206−172679) deaths for males, and 52271 (211296−159025) deaths
for females in 2000, (this is the difference between the total of expected deaths in
combination h and the 2000 model estimated prevalence rates). Column i in Tables
6.16 and 6.19 shows the number of deaths when smoking is also added in the com-
bination with other 1981 risk factors intensities. The numbers of deaths increase by
101157 (273836−172679) and 64924 (223949−159025) for males and females, respec-
tively, and are close to the 1981 model estimated prevalence rates. Figure 6.33 shows
the mortality rates for each combination and we can see that the mortality rates are
closer to 1981 as we add in more factors to the combination. Overall, mortality rates
have decreased from 1981 to 2000 while the prevalence of IHD for males has changed
very little over this period. However, if we take out the changes in other risk factors,
the prevalence of IHD would have increased (Table 6.7). This worsening morbidity
has been more than offset, in terms of mortality, by the reduction in the probability
of sudden deaths which occur probably due to better medical treatments.
When we add smoking at the start of our combinations, we can see in Tables 6.17
and 6.20 that it increases the figures in all age groups and in each combination as
smoking rates are higher in 1981. By including smoking, it has given the highest effect
to the combinations in which we add BMI and hypertension where the difference for
males with the case where smoking is not included is 1049 (13423−12374) and 1693
(14762−13069) deaths, respectively. These are calculated by finding the difference
between the difference with previous combination in column b in Table 6.16 and
column b* in Table 6.17 for combination with BMI and between column d in Table
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6.16 and column d* in Table 6.17 for combination with hypertension. It also affects
mortality by increasing the number of deaths by 5553 (57993−52440) for males and
2486 (53010−50524) for females when smoking is included. Figures 6.34 and 6.36 show
the mortality rates for each combination in which we add smoking at the beginning of
the combination for males and females, respectively. The model estimated mortality
rates for each combination are higher than the model estimated mortality rates shown
in Figures 6.33 and 6.35 in which 1981 smoking rates are added at the end of the
combination.
Until now, we have used the 1981 risk profiles as the intial risk profiles to run the
HW model. We can also run the model using the 1961 risk profiles. Tables 6.18 and
6.21 show the expected number of deaths when we use 1961 risk profile as the initial
risk profile to run the HW Model for males and females. With the 1961 initial risk
profile, there are higher expected deaths in all combinations compared to Tables 6.16
and 6.19 that use the 1981 observed prevalence rates. The highest difference with
the previous combination is in combination b where the difference is 19586 (Table
6.18) compared to 12374 (Table 6.16) when we used 1981 risk profile for males. In
combination e, hypercholestrolaemia prevalence in 1961 risk profiles has increased the
expected deaths for males from previous combination which is different from the the
result in Table 6.16. In column i, we can see that the expected number of deaths is
very close to the result from the 1981 model estimated prevalence rates for males and
females.
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Figure 6.33: Effect of changes on mortality (males).
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Figure 6.34: Effect of changes on mortality with 1981 smoking (males).
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Figure 6.35: Effect of changes on mortality (females).
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Figure 6.36: Effect of changes on mortality with 1981 smoking (females).
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Age group 2000 a b c d e f g h i 1981
45-54 12620 13921 13648 13629 16252 16001 16404 14874 14986 16517 17779
55-64 24327 27272 26142 25831 30056 29704 34374 33254 37418 43171 46668
65-74 50042 56293 53749 52645 57280 56630 65345 60297 75756 86966 94573
75-84 85689 95654 91514 89511 91098 90784 94787 82341 115046 127182 129434
Total 172679 193140 185053 181616 194685 193118 210910 190766 243206 273836 288454
Difference with previous combination 20462 12374 −3437 13069 −1567 17792 −20144 52440 30630 14617
Table 6.16: Expected number of deaths (males).
Age group 2000 a b* c* d* e* f* g* h* 1981
45-54 12620 13921 15052 15031 17925 17650 18192 16393 16517 17779
55-64 24327 27272 29285 28939 33701 33311 39752 38424 43171 46668
65-74 50042 56293 60354 59132 64406 63689 75623 69540 86966 94573
75-84 85689 95654 101873 99707 101539 101208 106332 91487 127182 129434
Total 172679 193140 206563 202809 217571 215857 239899 215843 273836 288454
Difference with previous combination 220462 13423 −3754 14762 −1714 24043 −24056 57993 14617
Table 6.17: Expected number of deaths with smoking 1981 at the start (males).
Age group 2000 a b c d e f g h i 1981
45-54 12620 14486 14121 14101 17343 17232 17724 16059 16188 17844 17779
55-64 24327 28865 27691 27371 32336 32334 37712 36458 41003 47317 46668
65-74 50042 60355 58142 57071 62047 62218 71931 66630 83103 94946 94573
75-84 85689 95748 92311 90452 92050 92656 97211 84482 117564 129897 129434
Total 172679 199454 192265 188996 203775 204440 224577 203627 257858 290003 288454
Difference with previous combination 26775 19586 −3269 14780 665 20137 −20949 54230 32146 −1550
Table 6.18: Expected number of deaths using 1961 initial risk profiles (males).
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Age group 2000 a b c d e f g h i 1981
45-54 9255 10153 9864 9842 10322 10316 10090 9161 9223 10042 10658
55-64 17864 19319 18339 18218 20294 20525 22632 20800 23460 25640 23779
65-74 39694 42130 40414 39905 44115 44723 49046 45390 57349 61208 58360
75-84 92212 97699 92804 91204 94252 95386 91859 85421 121264 127060 121281
Total 159025 169302 161422 159168 168983 170949 173627 160772 211296 223949 214078
Difference with previous combination 10277 2397 −2254 9815 1966 2678 −12855 50524 12653 −9871
Table 6.19: Expected number of deaths (females).
Age group 2000 a b* c* d* e* f* g* h* 1981
45-54 9255 10153 10815 10790 11319 11310 11040 9974 10042 10658
55-64 17864 19319 19825 19692 21952 22220 24799 22755 25640 23779
65-74 39694 42130 42879 42332 46837 47513 52508 48536 61208 58360
75-84 92212 97699 98297 96597 99899 101129 96626 89674 127060 121281
Total 159025 169302 171816 169412 180007 182173 184973 170939 223949 214078
Difference with previous combination 10277 2514 −2404 10595 2166 2800 −14034 53010 −9871
Table 6.20: Expected number of deaths with smoking 1981 at the start (females).
Age group 2000 a b c d e f g h i 1981
45-54 9255 10471 10202 10180 10672 10666 10436 9488 9570 10601 10658
55-64 17864 19911 18948 18829 20946 21181 23280 21437 24175 23809 23779
65-74 39694 44934 43141 42624 46886 47464 51677 48069 60518 58087 58360
75-84 92212 97496 92475 90900 93930 95038 91572 85136 120811 121932 121281
Total 159025 172812 164766 162533 172434 174348 176964 164129 215074 214429 214078
Difference with previous combination 13787 5741 −2233 9901 1914 2617 −12835 50945 −645 −351
Table 6.21: Expected number of deaths using 1961 initial risk profiles (females).
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6.3.8 Discussion
We have calculated the effect of changes in the risk factors intensities on the number of
IHD cases, stroke cases and mortality between 1981 and 2000. Among the risk factors,
smoking contributes the highest difference in the total number of deaths for males and
females if smoking rates in 1981 continue to persist in 2000. In the IMPACT model,
changes in risk factors prevalence between 1981 and 2000 have caused 35,944 fewer
total deaths from ages 45 to 84 where the biggest contribution comes from smoking.
The reduction in smoking has reduced mortality by 48.1% from the total deaths.
In the HW model, there are lower diabetes rates when we use the 1981 diabetes
intensities that will lower the total number of deaths for males and females. Therefore,
higher diabetes rates in 2000 will increase the number of deaths. This is similar to
the result from the IMPACT model where adverse trends in diabetes have increased
the IHD deaths in the IMPACT model. An increasing trend can also be seen in the
obesity rates where in the IMPACT model, there are additional deaths of 2097. In
the HW model, higher obesity rates will reduce the mortality rates as there will be
lower lightweight rates. Lightweight has higher mortality rates than obese in the HW
model so 1981 BMI intensities have higher number of deaths compared to 2000 model
estimated rates.
An additional total of 101157 deaths for males would have occured in 2000 if all
the 1981 risk factors intensities including smoking had remained the same in 2000.
For females, the number of deaths was reduced by 64,924 due to changes in the risk
factors between 1981 and 2000.
To summarize, we have Tables 6.22 and 6.23 that show the total expected number
of deaths for males and females from the HW Model and the IMPACT Model. Table
6.22 shows the results from Tables 6.16 and 6.19 taking the combination of risk factors.
Results for Table 6.23 are taken from the effect of single risk factors.
The results from the HW Model and the results from the IMPACT Model are not
directly comparable. Using the HW Model, we can calculate the effect of changes
for one risk factor only and also a combination of risk factors. We assume that the
1981 intensities continue to happen in 2000 and see what would have happened to the
number of IHD cases, stroke cases and number of deaths. In the IMPACT Model, the
number of deaths prevented or postponed are calculated for each change in each risk
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factor between 1981 and 2000.
In the IMPACT Model, a reduction of 34% in smoking between 1981 and 2000 has
prevented 29715 deaths. From our model, if smoking rates in 1981 continue to persist
in 2000, there will be 30738 more deaths. From Table 6.23, an obvious difference in
the expected deaths is from BMI. With IMPACT, there is a negative number of deaths
prevented or postponed which means the negative changes in obesity have increased
the number of deaths prevented or postponed by 2097. However in the HW Model, if
1981 BMI intensities continue to happen in 2000, there will be higher expected deaths,
as despite the obesity rates in 1981 being lower, lightweight has higher mortality than
obese in our model.
Risk factor HW Model IMPACT Model
Male Female Total Total
Smoking 20461 10277 30738 29715
Hypertension 13069 9815 22884 5868
Hypercholesterolaemia −1567 1966 399 7900
BMI 12374 2397 14771 −2097
Diabetes −3437 −2254 −5691 −2888
Table 6.22: Results from effect of combination of risk factors.
Risk factor HW Model IMPACT Model
Male Female Total Total
Smoking 20461 10277 30738 29715
Hypertension 12530 9497 22027 5868
Hypercholesterolaemia −1388 1877 489 7900
BMI 12374 2397 14771 −2097
Diabetes −3677 −2408 −6085 −2888
Table 6.23: Results from effect of single risk factor.
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Chapter 7
Conclusions
7.1 Conclusions
The adjusted HW model can be used to calculate the effect of changes in the risk
factors prevalence rates on IHD, stroke and mortality between 1981 and 2000. The
major risk factors associated with these conditions are age, sex, smoking, BMI, dia-
betes, hypertension and hypercholesterolaemia.
Among these risk factors, smoking is found to be the highest contributor affecting
the number of IHD, stroke and mortality. Almost 31,000 deaths for males and females
will happen if the smoking rates in 1981 continued to happen in 2000. This shows
that the reduction in smoking has saved these lives. It also suggests that the smoking
ban and promotion towards no smoking has shown a successful effect. The age range
that we have considered in our model has higher mortality rates for smokers with IHD
that the prevalence of IHD has decreased in 2000 especially for males.
Adverse effect is shown in diabetes as there would be 6,085 fewer deaths for males
and females if 1981 diabetes intensities continued to happen in 2000. More prevention
strategies need to be implemented to control the diabetes prevalence rates to keep the
prevalence rates from increasing over time. It is also important to lower the prevalence
of diabetes as it has a direct effect on IHD and mortality.
Hypertension has a direct effect on IHD, stroke and mortality, whereas hyperc-
holesterolaemia has a direct effect on IHD but not on stroke and a mixed effect on
mortality (Chatterjee et al., 2008(a), Tables 9 and 10). Hence, increasing the levels
of hypertension to 1981 levels will tend to increase the prevalence of IHD, stroke and
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number of deaths. 1981 hypercholesterolaemia levels increase the prevalence of IHD,
particularly for females, but have little effect on the prevalence of stroke or the num-
ber of deaths. Increasing the IHD levels to 1981 levels have different effects for males
and females as the trends over time are different for both males and females and the
numbers of deaths are affected by the adjustments for sudden deaths following MI
and stroke that are included in the adjusted HW model.
The HW model can be used to calculate the effect of changes in one single risk
factor and also a combinations of factors. The IMPACT model does not deal with
the changes in any combination of factors. Looking at the effect of changes in a
combination of factors can allow us to see the relation between these risk factors to
the changes in the numbers of IHD cases, stroke cases and deaths. The HW model
can be used to forecast the future prevalence rates for the risk factors in the UK as it
is adjusted to match the UK observed prevalence rates where as the IMPACT model
uses the β coefficient from various countries that might not represent the trend in
the UK over time. As for the time period, the HW model is more flexible as we can
choose any time period that we want.
Our model can be be applied to other countries by adjusting the intensities to
match the observed prevalence rates from that country or by calculating new param-
eterisations if data are available.
7.2 Limitations
Our model only includes people from ages 45 to 84. This is because we have to run
the model for 19 years (from 1981 to 2000) and to find the model estimated prevalence
rates for those aged 45 or below in 2000, we need to start at age 26 and below which
is not applicable to the HW model. The chosen age range is also used because there
are more cases of IHD and stroke in these age groups. We limit our upper age to 84
to follow the IMPACT Model.
Cancer is a major cause of deaths in the UK and other countries. At present, cancer
deaths are included in the mortality transition rates but cannot be differentiated in
the same way as IHD and stroke. The model could be extended to include cancer in
the future. Another limitation is that our model is not fully dynamic. We have two
static parameterisations of the model which, when applied to appropriate initial risk
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profiles, produce model estimated prevalence rates for 1981 and 2000.
7.3 Further research
We can consider future changes in our model by answering this question: what will
happen if the intensity of some factor changes in the future? This will be based on
research findings and medical advances for the prevention of the risk factors. For
example, the introduction of statins in the 1990s to lower cholesterol level could be
considered and we could explore how it affects the prevalence of hypercholestero-
laemia. A study on the polypill by Wald and Law (2003) stated that the polypill can
prevent the risk of IHD and stroke in middle–aged and older people and we could use
the model to see what happens in the future if these intensities change due to this
medical advance and the impact it has on the event rates. New law enforcements such
as the regulation of smoking, can also affect the future rates.
We can include other causes of death in our model to explain more about the
mortality rates in England and Wales such as cancer. We could also extend the upper
age limit by including those aged above 84 as longevity is increasing. We could also
make the model fully dynamic by making some or all of the transition intensities to
depend on calendar year. In the future, we could use the model to apply it to other
countries and this would depend on what data were available.
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